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ABSTRACT 
Lower incidence of breast cancer in Asia has been connected to the higher intake of 
isoflavone-containing soy foods. The effort to study soy isoflavones as health protective 
compounds has come to some positive results, like their effects in cancer prevention. 
lowering blood cholesterol level and osteoporosis prevention. In order to characterize the 
bioavailability of the third major isoflavone glycitein and to assess its potential health-
protective effects, a comparison study with other isoflavones was conducted in humans with 
moderate fecal isoflavone degradation activity. The average 48 h urinary excretions of 
daidzein, glycitein and genistein were 50, 45 and 35% of the total dose ingested, respectively, 
at which daidzein and glycitein were not different from each other but they were significantly 
greater than genistein {p = 0.01). Plasma isoflavone concentrations paralleled relative 
amounts of isoflavones in soymilk at 6 and 24 h but not in soygerm in women at 6 h. 
To characterize soy isoflavone metabolism, three feeding protocols were conducted in 
women. By using selective hydrolysis enzymes, the distribution of glucuronide and aglycone 
isoflavones in both urine and plasma were obtained. At 3 h after soymilk intake, 59.4% of 
total daidzein and 50.9% of total genistein appeared in plasma as glucuronides. About 76.8% 
of total daidzein and 70.9% of total genistein presented in urine (24 h) were glucuronides. 
Significantly higher percentages of aglycone appeared in plasma than in urine. A steady 
state was observed with sbc consecutive days feeding. As the major metabolite of isoflavone, 
the glucuronide forms might contribute to observed effects of soy isoflavones. 
The major metabolites of daidzein and genistein glucuronides were assayed for their 
ability to modulate human natural killer (NK) cells and NK3.3 cell line alone or in 
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combination with aglycone daidzein and genistein in nutritionally relevant concentrations. 
Daidzein and genistein glucuronides were as active as their aglycone counterparts but 
activated human NK cells in a wider range (up to 10 ^moI/L) than aglycone isoflavones 
(below 5 |amol/L). No activation was observed with NK3.3 cell line for both daidzein and 
genistein. These data suggested that soy isoflavone metabolites indirectly activated human 
NK cells. 
I 
GENERAL INTRODUCTION 
A. Introduction 
Expanding scientific knowledge has supported the idea that foods play a vital role in 
overall health and well being. Phytochemicals are nonnutritive secondary plant metabolites 
present in relatively small amounts. To date, most research related to phytochemicals has 
focused on cancer prevention. At least a dozen distinct classes of nonnutrient phytochemicals 
in fruits and vegetables with demonstrated anticancer activity have been identified (Stemmetz 
and Potter, 1991). Soybeans contain several classes of phytochemicals. such as saponins, 
protease inhibitors, isoflavones and inositol hexaphosphate (phytates). The main forms of 
isoflavones foimd in soybean are daidzin, genistin, glycitin, malonyl- and acetyl-glucosides and 
their corresponding aglycones daidzein, genistein and glycitein. Consumption of soybean 
isoflavones has been associated with several health-enhancing properties such as lowering the 
rates of breast, colon and prostate cancers (Barnes et al., 1994); reducing blood cholesterol 
level and decreasing the risk of cardiovascular disease (Potter et al.. 1998); prevention of 
osteoporosis and reduction of post-menopausal symptoms (Messina and Messina, 2000). 
It was found that the content of the total isoflavones and different forms of isoflavone 
differ in soybeans based on source, variety and year (Wang and Murphy, 1994a). The 
bioavailability and biological activities of different forms of isoflavone also differ to some 
extent. Bioavailability refers to the portion of a substance absorbed that reaches its active 
sites. Bioavailability studies have been performed for daidzein and genistein. But the 
bioavailability of the third major isoflavone, glycitein, has not been studied at all. To compare 
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glycitein bioavailability and metabolism with other isoflavones to begin to understand this 
compound is one of the objectives of my research. 
After absorption, over 95% of the isoflavones appear as conjugated forms (mainly as 
glucuronides and less as sulfetes) in the circulation in cow and sheep (Lundh,1995). The 
percentage of conjugates in human urine and plasma was estimated to be over 90%. but no 
definite number is known because most of the studies used hydrolysis enzymes to obtain 
aglycones and all the results were reported as aglycones. Classically, conjugation has been 
considered as a detoxification step. But in some cases, after conjugation, the biological 
activities of the conjugates have been enhanced. The formation of aromatic amine 
glucuronides can cause bladder cancer (Thorgeirsson et al., 1983). Retinoyl P-glucuronide 
(RAG) and retinyl P-glucuronide (ROG) were more active than their parent compounds in 
inhibiting prolactin-induced DNA synthesis in organ cultures of mouse mammary glands 
(Olson et al., 1992). Daidzein and genistein glucuronides showed some biological activities in 
in vitro assays including weak estrogenicity and natural killer (NK) cell modulation activity 
(Zhang et al.. 1999a). To our knowledge, research about isoflavones has focused on the 
biological activities of daidzein, genistein and equol. However, the concentrations that have 
been applied in many studies were very high, such as 0.15 mmoI/L genistein used as a MCF-7 
cell cycle arrest agent (Constantinou et al., 1998b). It will be crucial for us to know the 
amount and percentages of both aglycones and conjugated isoflavones in the circulation in 
order to understand isoflavone biological activities, especially their anticancer effects. To 
measure the amount of glucuronide as well as aglycone isoflavones in circulation after 
different feeding protocals is another objective of my research. 
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Natural killer (NK) cells are the third major class of lymphocytes after T and B cells 
and comprise 10-15% of the lymphocyte population in blood, liver, and especially in the 
spleen in humans. NK cells have nonspecific cytotoxicity and represent one of the first lines 
of immune defense against tumor cells and virally infected cells in the body. Previously we 
reported that genistein at concentrations ofO.1-5 ^M, daidzein and genistein glucuronides at 
concentrations of 0.1 -10 |iM were able to activate NK cells (Zhang et al.. 1999a). Based on 
our human feeding study results, daidzein, genistein and their glucuronides can all be detected 
in circulation. In order to best understand NK activation activity of isoflavones, it is our goal 
to investigate the effect of these four major isoflavone metabolites in combination on NK 
activity. Since previous studies of NK cells used were separated fi-om peripheral blood (i.e. 
not pure NK cell populations), by using a NK cell line we can clarify the direct effects of 
isoflavones on NK cell function as well. 
B. Dissertation organization 
This dissertation consists of a literature review and three papers. The first paper. 
"Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differs among 
humans with moderate fecal isoflavone degradation activity" has been published in Journal of 
Nutrition, 129: 957-962. The second paper. "Glucuronides are the main isoflavone 
metabolites in women fed soy milk powder" and the third paper, "The combination of 
daidzein, gem'stein and their glucuronides activated human natural killer cells in nutritionally 
relevant concentrations" will be submitted to Journal of Nutrition. A general conclusion 
follows the three papers. 
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LITERATURE REVIEW 
A. Plant and commercial food product sources of isoflavones 
The flavonoids are a major class of phenylpropanoid-derived plant products. Their 
fifteen carbon (Ce-Cs-Ca) backbone can be arranged as a 1,3-diphenylpropane skeleton 
(fhvonoid nucleus) or as a 1,2-diphenylpropane skeleton (isoflavonoid nucleus). The 1.3-
diphenylpropane flavonoid derivatives are mainly found in terrestrial plants. The isoflavonoids 
are primarily restricted to the Leguminosae, rarely they can be found in other families such as 
Apocynaceae, Pinaceae, Compositae, and Moraceae (Dixon et al.. 1999). 
There are nearly 900 natural isoflavonoid aglycones, which can be divided into nine 
major classes based on differences in their basic carbon skeletons. The isoflavones and 
pterocarpans are the most abundant isoflavonoids. with 334 and 152 different structures, 
respectively. These diversities are caused by various substituents that occur on many different 
positions of the A and B rings (Fig. 1), such as methoxyl, prenyl and methylenedioxy. 
Clover is one of the legume plants, consumed by animals, especially sheep, that 
contains relatively high amount of isoflavones. Isoflavones are high in subterranean clover, 
for example, the Yaloop cultivars contained 1.5, 2.8 and 0.5% of dry matter as formononetin, 
gerustein and biochanin A, respectively. In red clover, and relatively less in white clover, such 
as the red clover Ladino cuhivar contained about 0.02, 0.01 and 0.02% of dry matter as 
formononetin, genistein and biochanin A, respectively (Cheeke, 1985). The amount that is 
present in clover depends upon many factors. Rossiter and colleagues in a series of studies 
from 1966 to 1973 have thoroughly examined the environmental 
5 
Common isoflavone aglycones 
R O 
Compounds R1 R2 R3 R4 
Daidzein OH H H OH 
Genistein OH H OH OH 
Glycitein OH OCH3 H OH 
Biochanin A OH H OH OCH3 
Formononetin OH H H OCH3 
Figure I: Chemical structure of isoflavone and common isoflavone aglycones 
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influences on the isoflavone levels in subterranean clover. The concentrations of isoflavones, 
especially formononetin. in the fiiUy expanded leaf were increased markedly by mineral 
deficiencies of nitrogen, sulfur, and especially phosphorus. The effects of potassium, zinc and 
copper on isoflavone concentrations were negligible. Both high and low temperatures and 
ver>' low light intensities usually lowered isoflavone levels. The concentrations of isoflavones 
vary within the plant, being highest in the leaves, intermediate in flowers, and lowest in 
petioles, stems and roots. Also, genetic background (Morley and Foaucis, 1968) and growth 
stages (Hanson et al., 1965) play an important role in isoflavone concentration variations. For 
soybeans, the location and crop year also influence the content of isoflavone present (Wang 
and Murphy, 1994a). 
Soybean is the major plant seed consumed by humans which contains high amounts of 
isoflavones. The amount of isoflavones present in soybeans is about 1-3 mg/g (Wang and 
Murphy, 1994b). The major isoflavones found in soybeans are the polar glycosylated forms: 
daidzin, genistin. glycitin, malonyl- and acetyl-glucosides of these forms and their respective 
aglycone forms: daidzein. genistein and glycitein. Most of the soy isoflavones are 
concentrated in the hypocotyl and are four times more concentrated than in the cotyledons, as 
reported by Kudou et al. (1991). Glycitein and its glucoside derivatives are mainly found in 
the hypocotyl. 
The distributions of the isoflavone isomers in commercial soybean foods are quite 
different. In soy germ, glycitein is the predominant form with daidzein second highest and 
genistein the minor form with a ratio of 50:40:10. Soy ethanol extract (from Novasoy) has an 
isoflavone distribution with genistein:daidzein:glycitein in a ratio of 50:40:10. which is 
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comparable to soybean isoflavone distribution (Hendrich and Murphy, 2000). The total 
amount and/or the forms of isoflavones may be altered during food processing. The 
isoflavonoid moieties of isoflavone glucosides are not destroyed by most conventional food 
processing operations. The concentrations of the acetyl glucosides are increased in toasting 
soy flakes (Farmakalidis and Murphy, 1985). Malonylglucosidc is converted to the p-
glucosides in an equimolar distribution with a minimal heat processing (Wang and Murphy, 
1996). Microbial enzyme can hydrolyze the glucosides to produce aglycones in fermented 
products like tempeh, miso and natto (Buseman, 1996; Wang and Murphy, 1996). 
Soy ingredients, which include raw (or unprocessed) soybeans, soy flours (defatted 
and flill fat), soy concentrates, soy isolates, texturized soy protein (TVP) and hydrolyzed soy 
protein, contain the highest concentrations of isoflavones with a total normalized isoflavone 
content ranging from 466 fig/g to 1640 |ag/g. The isoflavones tend to associate with the 
protein fraction in soybeans. The higher the fat content, the less isoflavones will be detected. 
Soybean oil contains no detectable isoflavones. while the defatted soy flour contain the highest 
concentrations of isoflavones. The extraction solvents also have a big influence on isoflavone 
concentrations. Isoflavones have a high solubility in alcohols. Alcohol washed soy 
concentrate contains little isoflavone (Hendrich and Murphy, 2000). 
Traditional soy foods, which have been widely used in Eastern Asia, including tofii. 
soymilk. tempeh, miso, natto, soy sauce, soynuts (roasted or fried soybean) and kinako also 
have significant amounts of isoflavones with a range of 100 [ig/g to 1600 |ag/g (Hendrich and 
Murphy, 2000). The level of isoflavones in these products depends on the isoflavone 
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concentrations of the starting soybean. Kinako, which comes from toasted soy flour, has the 
highest isoflavone content (2438 ng/g wet weight). The fried or roasted soynuts are whole 
soybeans and are concentrated with the loss of water, so they have the highest isoflavone 
concentrations among available food products (Hendrich and Murphy, 2000). 
The second generation of soy foods are foods where soy protein is used to replace 
muscle or dairy proteins. The most widely available products are soy hot dogs, soy burgers, 
soy bacon, soy/beefburger blends, soy cheese and other soy meat analogues. These products 
are low in isoflavone content with less that 100 |ig isoflavones per g of product due to the 
small amount or low isoflavone level in the soy protein ingredients being used. Interestingly, 
the soy infent formulas, which use soy isolate as the replacement for dairy proteins, contain 
relatively high amounts of isoflavones ranging from 214 ng/g to 285 ng/g of dry formula 
among the six major brands marketed in the United States (Murphy et al., 1997). 
Reduced fat soy foods have been a great attraction to consumers due to their low- or 
no-fat content. These products like soymilk and tofti can be produced by different processing 
methods, such as skimming the soymilk to reduce fat or adding soy isolate/soy concentrate to 
increase protein concentration and dilute fat concentration. The total amount of isoflavones 
varies in each product, with a range of 700 to 1800 ng/g product (Hendrich and Murphy, 
2000). 
Dietary supplements can also be found in the market and are available to consumers. 
These supplements (about 100 options in U.S.) are coming from different sources with 
different concentrations and distributions of isoflavones. The major sources are soy germ or 
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soy hypocotyl produced by Schouten Company, soy ethanol extract marketed as ""Novasoy". 
red clover and Kudaox (an Asian plant) extract. Compared with any other food sources of 
isoflavones, these isoflavone supplements are tenfold or more concentrated (Hendrich and 
Murphy, 2000). 
The role of isoflavones in plants is not obvious. They frequently form a substantial 
proportion of the dry matter of the plant, which has suggested that isoflavones are simply 
storage compounds. However, isoflavones are synthesized primarily during active growth 
when demand for carbon is greatest and not at maturity when carbon is available for storage, 
suggesting that they may play important roles in the life of plants. The isoflavones from red 
clover may inhibit the germination of its own seed (Change et al., 1969). Isoflavones can act 
as stimulatory as well as inhibitory factors in legume and fimgi interactions (Dixon te al., 
1999). Daidzein and gerustein, released in soybean root exudates, act at nanomolar 
concentrations as chemoattractants for zoospores of phytophthora sojae, and also induce their 
encystment and germination (Morris and Ward, 1992). Biochanin A and several pterocarpan 
phytoalexins. including medicarpin and pisatin, stimulate germination of Fusarium solani 
spores at micromolar concentraions (Ruan et al., 1995). Isoflavones may also inhibit the 
action of microorganism invasion and function as phytoalexins (Barz and Welle, 1992). 
Daidzein and genistein are also reported to inhibit the ability of Rhizobium bacteria to induce 
root nodules ((Firmin et al., 1986). On the other hand. Bradyrhizobium sp. has been reported 
to be attracted to the plant to form root nodules when specific flavonoids and isoflavonoids 
are secreted from the plant roots. Isoflavones in soybean function as inducing compounds of 
nod genes, a common gene required for the early stages of nodule formation, in 
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Bradyrhizobium japonicum (Kosslak et aL, 1990) and as precursors of inducible pterocarpan 
phytoalexin, glyceollin I-III (Ebel and Grisebach, 1988). Reduced synthesis of daidzein in 
soybean roots at suboptimal temperatures limits rhizobial colonization (Zhang and Smith, 
1996). 
Isoflavone biosynthesis has been extensively studied in chickpea and soybeans. .A. 
phenyl-propanoid pathway has been proposed and chalcone synthase (CHS), chalcone 
reductase (CHR) as well as isoflavone synthase have been identified as the key enzymes (Braz 
et al.. 1990; Ebel et al., 1986). CHS catalyzes the formation of chalcone by a head-to-tail 
condensation of 4-coumaroyl CoA and three molecules of malonyl CoA. CHS has been 
purified, characterized and its gene cloned from many plant species (Dixon et al., 1998). CHS 
is encoded by multigene families, consisting of at least seven in soybeans. The multiple forms 
of CHS in legumes may have evolved to serve particular specializations of the 
flavonoid/isoflavonoid pathway, but there is no direct evidence currently to support this 
hypothesis. In addition to the formation of naringenin chalcone, in the presence of high 
concentration of NADPH and the enzyme of CHR, 2',4,4'-trihydroxychalcone and its 
corresponding flavanone liquiritigenin are also produced. CHR is encoded by a small gene 
family in soybean and alfalfa. This enzyme co-acts with CHS and exhibits approximately 90% 
maximal activity at a molar ratio (CHS : CHR) of 2 :1 (Dixon et al., 1999). The third 
important enzyme in isoflavone synthesis is isoflavone synthase. It catalyzes the conversion of 
naringenin to genistein or 2(S)-Iiquiritigenin to daidzein, in the presence of NADPH 
(Hagmann and Grisebach, 1984). To date, there is no report on the purification to 
homogeneity or the molecular cloning of the gene for this enzyme. These aglycones can 
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undergo glucosylation in the T- 0-position to form the predominant glucoside forms of 
isoflavones in soybean. Further methylation at the 4'-position of daidzein and genistein, 
catalyzed by 4'-isoflavone methyitransferase, yield formononetin and biochanin A, respectively 
(Wengenmayer et al., 1974). 4'-0-methyIation appears necessary prior to further 
modification of the isoflavonoid nucleus by 2'-hydrox>'lation and subsequent reduction to 
isoflavanone, the substrate for formation of pterocarpans (Hinderer et al., 1987) (Fig 2). 
B. Metabolism of isoflavones 
Most of the isoflavones occur in soybean as glycosides and aglycones. as stated above. 
In ruminants, the glycosides are hydrolyzed by gut microflora! P-glucosidases in the nmien 
and fluther demethylated and reduced by the microorganisms. A very minor portion of these 
hydrolyzed isoflavones is absorbed very quickly from the rumen, and reaches the circulation 
unconjugated. The bulk is conjugated in gastrointestinal epithelium by phase II 
biotransformation en2ymes, namely UDP-glucuronyltransferases (UGT) and sulfotransferases 
(SULT) (Fig 3). The remaining unconjugated isoflavones that enter the circulation axe mainly 
conjugated by the liver and perhaps also by other extrahepatic tissues such as kidney. Lundh 
(1995) reported that in cattle and sheep, the conjugation of isoflavones mainly happened in 
gastrointestinal epitheliimi, which indicated that the liver was not the predominant detoxifying 
organ for isoflavones in ruminants. When rats were infused intestinally with labeled 
genistein, 70% of the labeled genistein was found in its glucuronidated form from the 
collected portal blood (Sfekianos et al., 1997). Thus, the intestinal mucosa was the major site 
of isoflavone biotransformation in rats. 
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Figure 2: Biosynthesis pathway of isoflavone daidzein and genistein. 
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Figure 3. Metabolic pathways of dietary isoflavones (adapted from Setchell and Adlercruetz. 
1988). 
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Doerge et al. (2000) evaluated substrate activities of daidzein and genistein with 
recombinant human UGT and SULT. The human colon UGT 1 AlO isoform was found to be 
specific for genistein, although several other UGTs (1 Al, IA4, 1A6, IA7, 1A9 and 1 AlO) 
catalyzed 7 and 4'-glucuronidation of both daidzein and genistein. The SULTs 1 Al*2, IE 
and 2A1 catalj-zed formation of a single genistein sulfate; the 1A2* 1 and 1 A3 isozymes had 
no observed activity. None of the SULTs listed above showed any activity with daidzein. 
Clearly, there were tissue and enzyme isoform specificities towards the conjugation of 
daidzein and genistein. 
Based on the observation by Sfakianos et al. (1997) that 75% of a dose of '•*€-
genistein was recovered fi-om bile within 4 h after duodenal infusion of rats, bib'ary excretion 
may be considerable. The biliary isoflavone metabolite of genistein was the 7-0-glucuronide. 
However, human feeding studies (Xu et al.. 1994. 1995a & b) showed that the recovery of 
isoflavones fi-om feces is usually nearly nil. With about 10-50% of ingested isoflavones 
recovered fi^om urine, this suggests that biliary excretion of isoflavones is followed by the 
breakdown of isoflavones by some microorganism, namely Clostridium, Butyrivibrio and 
Eubacterium (Hawksworth et al., \91\). 
Glucuronidation is the major detoxification system for several potentially toxic 
endogenous and exogenous substances, including phytoestrogens. Formononetin, daidzein 
and equol are mainly found as glucuronide conjugates in blood. Not more than about 5% of 
the total amount was found as unconjugated substances in plasma at any time (Lundh, 1995). 
However, different species may differ in their ability to metabolize isoflavones. Studies 
performed by Cimino et al. (1999) showed that man and rat excrete different amounts of 
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genistein, daidzein and their conjugates from urine. Twenty-six female rats fed isolated soy 
protein, which contains 1.36 and 0.65 mg of genistein and daidzein equivalent per g protein, 
excreted genistein and daidzein: 52±4 and 42±3% as free aglycones, 28±3 and 18±4% as 
glucuronides, 26±4 and 40±3% as sulfates, respectively. The male human subject excreted 
genistein and daidzein: 0.36 and < 1% as free aglycones, 86 and 75% as glucuronides, 4 and 
11% as sulfates. Peterson et al, (1998) reported that they could detect genistein 7-suIfate 
after incubating MCF-7 and T47D human cancer cell lines with genistein; but the hydroxylated 
and methylated metabolites were suggested as the active forms of genistein in inhibiting cell 
growth. 
Basically, the mode of formation of isoflavone metabolites in humans seems to be 
similar to that in rats. Administration of soy protein resulted in a marked increase in the 
excretion of equol (a metabolite of daidzein formed by intestinal bacterial action) (Axelson et 
al., 1984). Some subjects may not be able to form equol (Axelson et al., 1984) and germ-free 
rats did not excrete equol when given commercial pelletted food (A.xelson and Setchell, 
1981). 0-desmethylangolensin (ODMA) seems to be a minor metabolite in man (Adlercreutz 
et al.. 1986). 
Different isoflavone components in food may produce different metabolites. When 
Yasuda et al. (1994) orally administered male Sprague-Dawley rats (120-160 g) with daidzein 
(60 mg/kg), the urine contained daidzein 7-0-P-D glucuronide, daidzein 4'-0-sulfate and 
daidzein. The urine of rats treated with daidzin (100 mg/kg) contained daidzein 7, 4'-di-
sulfate and the other three compounds mentioned above. 
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Rat intestinal microflora culture study has confirmed some of the metabolites of 
isoflavones. p-Ethylphenol, a metabolite of genistein was identified by paper chromatography 
and thin layer chromatography (TLC) and confirmed by gas chromatography (GC). 
Unfortunately, the presence of this metabolite in human urine has not been established 
(Heinonen et al., 1999). Equol was also detected (Griffith and Smith, 1972) in rats, and 
human (Heinonen et al., 1999). The tentative identification of/rans-4-OH-equol in human 
urine were reported by Kelly et al. (1993) and Joannou et al. (1995) based on their GC-MS 
spectrometric data and microscale synthesis of possible reference compounds. In 1998, 
Wahala et al synthesized cis- and rra/w-4-OH-equol and characterized them by 2D'H and 
'^NMR and MM calculation. Heinonen et al. (1999) fed six healthy volunteers with three soy 
bars (39 g) per day for 2 weeks and analyzed their two consecutive days urine samples. They 
isolated and characterized the urine metabolites with absorption chromatography on Sephadex 
LH-20 and gas chromatography-electron ionization mass spectrometry (GC-EIMS), and 
found that the known and previously authentically identified isoflavones daidzein, genistein, 
glycitein, equol, ODMA, dihydrodaidzein (4', 7-dihydroxyisoflavanone) and mammalian 
lignans enterolactone and enterodiol. They also isolated and characterized cis-4-OH-equol, 
dihydrogenistein (4', 5' 7-trihydroxyisoflavanone), and 6'-0H-0DMA fi-om these urines. 
Dihydrodaidzein and dihydrogenistein were identified in all the urine samples and were found 
to be the main metabolites of daidzein and genistein, respectively. However, the levels of 
genistein, dihydrogenistein and 6'-0DMA were especially low when compared to the levels of 
daidzein and its metabolites, although almost equal amounts of daidzein and genistein were 
ingested (41.4 and 34.4 mg per 100 g bar, respectively). Kelly et al. (1993) reported in their 
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Study that dfliydrogenistein was only a minor metabolite and they only identified this 
metabolite in the urine of one volunteer. This result was in disagreement with the result of 
Heinonen et al. (1999). It seems that feeding methods and chemical extraction and 
quantification methods greatly influence the identification and characterization of isoflavone 
metabolites. Standardizing analysis methods will facilitate isoflavone research. 
C. Isoflavone bioavailability 
Bioavailability is the proportion of a substance having access to its sites of action. 
Isoflavone bioavailability is a major determinant of the safety and eflBcacy of these 
compounds. Many factors might influence isoflavone bioavailability, such as structure, dose, 
background diet, soy food type, and gut microflora. 
In most soy foods, more than 90% isoflavones are in glycosidic form. These 
glycosides are probably poor substrates for mammalian P-glycosidases. They must be cleaved 
by gut microflora P-glycosidases before the isoflavone aglycone can be absorbed. 
Farmakalidis et al. (1985) showed that daidzin and genistin. when fed in equivalent molar 
amount, had the same estrogenicity in mice as did their respective aglycones. This suggested 
that cleavage of glycosides to aglycones by gut microflora! P-glycosidases was efiRcient. King 
et al. (1996) observed nearly identical total urinary excretions when they fed 20 mg/kg body 
weight genistein or equivalent dose of genistein glucoside forms to 10-wk old Wistar rats. 
Yasuda et al. (1994) had similar observation about daidzein and daidzin with their male SD 
rats (120-160 g) which were fed either 100 mg/kg daidzin or 60 mg/kg daidzein- Neither 
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Study reported urinary excretion of isoflavone glycosides. In general, the glycosides would be 
considered to have less biological activity due to their greater hydrophilicity and molecular 
weight, and have been shown to have less antioxidant activity than did the aglycones (Nairn et 
al., 1976). The direct absorption of glycosides has not been reported so fer. On the other 
hand, aglycones may be absorbed more rapidly than isoflavone glycosides. King et al. (1996) 
saw a higher initial plasma concentation at 2 h in genistein-treated rats (11.0 jimol/L) than in 
soy extract-treated rats (4.93{imol/L). But similar long-term concentration existed for both 
forms of isoflavones, indicating that their overall bioavailability may be the same. 
Isoflavone aglycones are slightly different in their structures (Fig. 1). Genistein has 
three hydroxyl groups and daidzein has two. The 5-OH group on genistein makes it more 
susceptible to microbial breakdown (Griffiths and Smith, 1972). More degradation of 
genistein makes it less available in the system. Based on urinary excretion, daidzein is more 
bioavailable than genistein. 
Many feeding studies have been performed to look at the influence of dose on 
isoflavone excretion and plasma concentrations. Two review papers have summarized the 
results (Hendrich et al.. 1999a and 1999b). Basically, at nearly equal doses, urinary excretion 
of daidzein was more than twofold greater than genistein. Plasma concentrations and urinary 
isoflavone levels were linearly related to isoflavone doses. Frequent intake will prolong 
isoflavone retention in the body. 
The low recovery of isoflavones from feces and the recovery of only 10-50% of 
ingested isoflavones from urine in human feeding studies indicated that these compounds may 
be degraded or significantly altered by gut microflora. Flavonoids and isoflavonoids may be 
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susceptable to degradation by strains of Clostridium, Butyrivibrio and Eubacterium 
(Hawksworth et al., 1971). In vitro anaerobic incubation of human feces with brain/heart 
infusion (BHI) media showed that daidzein completely disappeared after 72 h and genistein 
after 18 hrs. The disappearance of isoflavone fits first-order kinetics, with half-lives of 
daidzein and genistein estimated to be 7.5 and 3.3 h, respectively (Xu et al., 1995). Samples 
taken fi-om 15-20 subjects over a ten-month period showed that people could be grouped into 
three different phenotypes according to their isoflavone degradation rate as assessed by in 
vitro fecal incubation (Hendrich et al., 1998). The rate constant, k, was calculated as the 
negative slope of the regression line plotted for isoflavone content of each sample over time. 
At day 0, daidzein degradation rates were: kiow = 0.012. kmodetaie = 0.055 and khigh = 0.299; for 
genistein, they were: kio^ = 0.023, kmodenue = 0.163 and kh,gh = 0.299. Within each compound, 
each phenotype differed significantly (p < 0.05) fi:om other phenotypes. At day 300, similar 
patterns were seen. These data suggested that human gut microflora differ in ability to 
degrade isoflavones in a relatively stable way. The degrees and strains of human gut 
microflora vary fi-om individual to individual, which highly influence the metabolism and 
bioavailability of isoflavones. However, which microorganism(s) are the major ones 
responsible for isoflavone degradation remains to be determined. 
Based on this phenotype identification method, Zhang et al. (1999b) selected 15 
subjects (7 male and 7 female) who are all moderate excretor phenotypes to participate in a 
human feeding study. In this study, except for a controlled amount of soyfoods, diet intake 
was ad libittim. Individual isoflavone urinary excretion varied about 8-fold for all three major 
isoflavones, daidzein, genistein and glycitein. In a diet-controlled study, Karr et aL (1997) fed 
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different levels of soy protein to 14 subjects. They found that urinary excretion of genistein 
varied by as much as 12-fold, daidzein by 15-foId within diet treatment. Compared to Karr's 
study, screening subjects to control for isoflavone degradation phenotype seemed to 
decreased isoflavone excretion variability to some extent, f^e-screening for degradation 
phenotyope could be a useful tool in studying isoflavone bioavailability. 
Gastrointestinal (GI) bacteria play an important role in determining the magnitude and 
degradation pattem of isoflavone bioavailability. Extensive metabolism and degradation of 
isoflavones by intestinal microflora, as occurs in the low excretor phenotype in vitro, prohibits 
isoflavone absorption. In this case, low fecal isoflavone and lesser total urinary recovery may 
be observed. Xu et al. (1995a) examined seven women fed a dose of 10, 20 and 30 |imol 
isoflavones/kg one day. They found that two subjects showed about two- to three-fold 
greater urinary isoflavone excretion of both daidzein and genistein than the other five subjects. 
This was accompaned by 10-fold greater recovery of isoflavones in their feces compared with 
other subjects. 
King et al. (1998) investigated the plasma and urinary kinetics of daidzein and 
genistein in humans by feeding them a single soy meal. Isoflavone concentrations in plasma 
rose slowly and reached maximal values of 3.14 |amol/L at 7.42 h for daidzein and 4.09 
^mol/L at 8.42 h for genistein. Urinary excretion rate of daidzein was greater than that of 
genistein throughout of postmeal period, with mean recovery of 62% and 22% for daidzein 
and genistein, respectively. The ratio of the areas under curve for plasma concentrations vs 
time for daidzein and genistein was equal to the ratio of the concentrations of the respective 
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isoflavones in the soy meal. They concluded that daidzein and genistein bioavailability were 
similar even though daidzein had greater urinary excretion. 
Biliary excretion of isoflavones occurred in rats as well as humans. The first-pass 
effect, the fraction of ingested isoflavones entering hepatic portal circulation from the intestine 
th.at is immediately passed hack out into the intestine by biliary excretion, may be 
considerable. Sfakianos et al. (1997) studied disposition of 4-''*C-genistein infused into the 
duodenum of rats. This '"'C-genistein was rapidly absorbed from the intestine, taken up by the 
liver and excreted into the bile as 7-0-P-glucuronide conjugate. The total recovery of'•*€-
radioactivity within 4 h in bile was 70-80% of the administered dose. The total urinary and 
fecal '"^C-genistein excreted from rats in metabolic cages within 120 h after dosing were 21% 
and 2%, respectively. Considering the recovery observed in human studies, a total of less than 
50% of ingested isoflavones in urine and nearly nil from feces (Xu et al., 1994, 1995a, 1995b) 
suggests that biliary excretion of isoflavones is followed by microbial breakdown. 
D. Anticancer effects and mechanism of isoflavones 
Diet has been considered to play an important role in cancer prevention. Although 
high intake of fruits and vegetables has been associated with lower cancer risk (Willett, 1994), 
evidence also suggests that higher intake of isoflavones from soy-rich diets can decrease the 
incidence of hormone-dependent cancers, such as breast, colon and prostate cancers. British 
intake of isoflavones has been estimated to be < 1 mg/day (Jones et al., 1989), while the 
average consumption of these compounds in Asian countries is 50-100 mg/day (Barnes et al., 
1990; GrifSths et al., 1999). Urinary equol excretion in Japanese was up to twenty times 
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greater than in Western populations, and the circulating levels of isoflavones in plasma were 
also much greater. In 1978, Nomura et al. found an association between greater intake of 
miso soup or tofu and subsequent decreased risk of breast cancer. Hirayama (1986) also 
showed that a high intake of soybean paste soup was associated with a reduced cancer risk in 
Japanese women. Lee et al. (1991) in their case-control study found a significant (p<0.01) 
association in premenopausal women between decreased breast cancer risk and greater 
soybean protein intake. These epidemiological observations have been verified by animal 
experiments. 
N-methyinitrosourea (NMU)-induced mammary tumor load in female rats was reduced 
from 8 to 3 by feeding 20% powdered soybean chips compared with a diet containing casein 
(Barnes et al., 1990). However, when the isoflavones were chemically extracted from the 
soybean product, no reduction in mammary carcinogenesis was observed (Barnes et al.. 
1990). Soybean protein isolate decreased mammary tumors by 50% in Sprague-Dawley 
female rats dosed with 40 mg NMU/kg body weight for 7 weeks compared to rats fed 20% 
casein (Hawrylewiez et al., 1991). When rats consumed a powdered soybean diet (15%), 
there was a 50% reduction in X-ray radiation induced mammary ttmwrs (Troll et al., 1980). 
Lamartiniere et al. (1995) also showed that administration of genistein (5 mg subcutaneous 
injection at day 2, 4 and 6 postpartum) to female Sprague-Dawley CD rats suppressed 
mammary cancer induced by dimethylbenz[a]anthracene (DMBA) (80 ng/g body weight at 
day 50), compared to vehicle-(dimethylsulfoxide) treated rats. 
In explaining the anticarcinogenic functions of isoflavones, several mechanisms have 
been proposed. Initially, isoflavones, especially genistein were considered to have estrogen 
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agonist/antagonist activity due to their structural similarity to the physiological estrogens such 
as 17p-estradioL, and to their estrogenic efifects (mouse uterine weight increase) when 1 or 2 
mg genistein, or 2 mg genistin was administered to immature female mice (Cheng et al., 
1953). However, other mechanisms have also been postulated, including protein tyrosine 
kinase (PTK) inhibition, topoisomerase II inhibition, induction of differentiation and 
antiproliferation, and inhibition of oxidation events. 
1. Antioxidant functions of isoflavones 
Hepatic neoplastic nodules from rats initiated with a single injection of 
diethylnitrosamine (DEN), 0.15 fimol/kg body wt, intraperitoneal) and promoted by 0.05% 
phenobarbital showed increased levels of reactive oxygen species (ROS), predominantly 
superoxide anion radicals (O;*^ and hydroxyl peroxide (HiOi), which was measured by the 
emission of lucigenin-chemiluminescenic signals (Scholz et al.. 1990). Certain ROS. such as 
hydroxyl radicals ("OH), Oi*" and H2O2, and their subsequent modification of macromolecules 
(such as protein, RNA and DNA) may be involved in development of multistage 
carcinogenesis (Fisher et al., 1988; Frenkel, 1992; Cerutti, 1985; Sun, 1990). Antioxidants 
may protect cells from the oxidative damage that occurs during carcinogenesis (Sun, 1990). 
Antioxidant effects of isoflavones may inhibit tumor promoter-induced oxidant formation and 
inflammatory responses which could lead to anticarcinogenic activities. Naim et al. (1976) 
reported that isoflavones inhibited lipoxygenase action and prevented peroxidative hemolysis 
of sheep erythrocytes in vitro. In female CD-I mice (6-7 weeks old) fed 250 ppm genistein 
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for 30 days, the activities of antioxidant enzymes including catalase, superoxide dismutase 
(SOD), glutathione peroxidase and glutathione reductase in skin and small intestine were 
enhanced about 10-30%. When comparing the effect of isoflavones on H2O2 production by 
12-0-tetradecanoylphorbol-13-acetate (TPA)-activated HL-60 cells and 02*" generation by 
:<anthine/xanthine oxidase, Wei et al. (1995) showed that genistein (IC50 = 25 ^moL'L) and 
daidzein (IC50 = 150 iimoi/L) were among the most potent inhibitors of hydrogen peroxide 
formation. Biochanin A and apigenin had little effect. They also showed that dietary 
administration of250 ppm genistein for 30 days significantly enhanced the activities of 
antioxidant enzymes in the skin and small intestine of mice. 
In 1996, Cai and Wei fed SENCAR mice with 50 or 250 ppm genistein for 30 days. 
The activities of antioxidant enzymes, such as catalase, SOD, and glutathione peroxidase in 
liver, kidney, lung and intestine were significantly increased compared to vehicle treated 
groups. The 4'-position hydroxyl group was proposed to be crucial for isoflavone antioxidant 
activity. 
Flavonoids and isoflavonoids may also have some effects on antioxidant protein 
expression. Kameoka et al. (1999) treated human intestinal Caco-2 cells with 100 ^mol/L 
genistein. daidzein, biochanin A or kaempferol and measured the mRNA level of 
metallothionein (MT), catalase and SOD. MT mRNA level was increased up to 15-fold by 
these compounds, but catalase and SOD mRNA levels were not affected. 
The antioxidant activities of isoflavones may also modulate the effects of glucose. Soy 
phytochemical extract (SPE) containing isoflavone daidzein and genistein was found to 
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protect against glucose-induced oxidation of human low-density lipoprotein in vitro. In this 
system, equol was as effective as dietary flavonols quercetin and kaempferol; it also had a 
similar antioxidant potency as endogenous 17p-estradioL, and was more effective than 
daidzein and genistein (Vedavanam et al., 1999). SPE was a weak inhibitor of glucose uptake 
into rabbit intestinal brash border membrane vesicles in vitro. The properties of isoflavone-
containing SPE as an estrogenic agent, an inhibitor of intestinal glucose uptake and a 
preventive agent for glucose-induced lipid peroxidation may make it a good candidate as 
antidiabetic agent(Vedavanam et al., 1999). 
2. Antiproliferation and differentiation induction properties of isoflavone 
Another main mechanism proposed for the anticarcinogenic function of isoflavones is 
antiproliferation and inhibition of cell growth. As the main transduction signal, increased 
activity of protein tyrosine kinases (PTKs) will give cells a proliferation advantage. As a 
specific inhibitor of tyrosine protein kinase (Akiyama et al.. 1986), genistein could act as an 
antitumor agent. 
Genistein is a more potent inhibitor of PTK than daidzein, so the investigation of 
antiproliferation activities of isoflavones has mainly focused on genistein, even though there 
are some reports about daidzein. Genistein inhibited the PTK activity of growth fector 
receptors, such as epidermal growth factor (EGF) receptor and pp**'"'®^ PTK (IC50 of 22-26 
pnol/L), and inhibited intact A431 PTK with an IC50 of 148 (imol/L (Akiyama et al., 1987 
and 1991). Aluminum tetrafluoride stimulated inositol phosphates in 3T3 cells inhibited by 
genistein and daidzein (Higashi and Oganara, 1992). Genistein (IC50 = 24-45 (imol/L) 
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inhibited both estrogen-and growth factor-stimulated proliferation of human breast cancer cell 
lines, including MCF-7, T47D ER", T47D ER", BT-20 and ZR-75-1 (Peterson and Barnes, 
1991 and 1996). However, the requirement for the presence of functional estrogen receptor 
or inhibition of epithelial growth factor PTK activity is not the only mechanism for the growth 
inhibition effect of genistein. Interfering with signal transduction events stimulated directly hy 
estradiol or growth factors may also account for the mammary cell growth blockage function 
of genistein. like the blockage of human colon cancer cell (Caco-2) proliferation stimulated by 
estradiol (Domenico et al., 1996). Estradiol triggered a rapid and transient activation of the 
mitogen-activated protein (MAP) kinases, erk-1 and erk-2. This activation was mediated by 
the estradiol receptor since it was inhibited by the pure antiestrogen ICI 181.780. Both erk-1 
and erk-2 are activated by receptor and non-receptor tyrosine kinase. It appeared that 
estradiol activated MAP kinases in Caco-2 cells was through stimulation of c-src kinase family 
members. Genistein (40 (amol/L), a src family kinase inhibitor, abolished the erk-2 stimulation 
induced by estradiol in Caco-2 cells (Domenico et al., 1996). 
Meng et al. (1999) synthesized fat-soluble isoflavone esters and incorporated these 
compounds via artificial transfer system into low density lipoprotein (LDL) and delivered 
them into U937 cells. LDL containing 7-oleates or 4'. 7-dioleates of genistein and daidzein 
significantly reduced U937 cell proliferation by 36-43%. The strongest inhibitory effect was 
shown by daidzein 4\ 7-dilinoleate with 93% reduction of cell proliferation. This in vitro 
study suggested that isoflavone fatty acid esters may transfer into cells via LDL-receptor 
pathway and exhibit their effects inside the cells. Whether this could occur physiologically 
remains to be seen. 
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The antiproliferative activity of isoflavones and flavonoids was probably not related to 
their structures either on basis of the classes or with respect to position of substitutions within 
a class (Kuntz et al., 1999) on cancer cell lines of Caco-2, MCF-7, LLC-PKl and HT-29. 
About 30 compounds they screened showed antiproliferation activities with EC50 values 
between 39.7 to 203.6 ^oL'L. In different cancer cell lines, flavonoids of the flavone, 
flavonoL, flavanone, and isoflavone classes possess different antiproliferative effects. Based on 
this study, the capacity of flavonoids for growth inhibition and induction of apoptosis also 
cannot be predicted on the basis of their chemical composition and structure. 
The other major cellular effect of isoflavones is to induce cell differentiation. 
Decreased activity of either topoisomerases, important enzymes in the process of replication, 
transcription, and other DNA processing, or tyrosine kinases have been implicated in the 
differentiation of a number of cell types (Markovits et al.. 1989). Genistein (18.5-74 jamol/L) 
induced erythroid differentiation of erythroleukemia cells (Watanabe et al., 1991). 
Myeloblastic ML-1 cells were induced to differentiate into promyelocytes, and pro myelocytic 
HL-60 cells were induced to differentiate into mature granulocytes by genistein (35 and 50 
|imol/L. respectively) (Makishma et al.. 1991; Constantinou et al., 1990). Mouse CI line cells 
which are megakaryoblastic cells established by coinfection of Abelson murine leukemia virus 
and recombinant simian virus were induced to differentiate and the v-abl tyrosine kinase 
activity was inhibited by genistein (4.6 jimol/L) (Honma et al.. 1991). Constantinou and 
Huberman (1995) investigated the diflferentiation induction by genistein in human 
promyelocytic HL-60, erythroid K-562 leukemia cell and SK-MEL-131 melanoma cells. The 
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optimal concentrations of genistein for each cell line were 31,21 and 55.6 jimol/L, 
respectively. They suggested that genistein triggers the pathway that leads to cellular 
differentiation by stabilizing protein-linked DNA strand breakage. 
The cellular level of p53 may be an important determinant of differentiation. Normal 
cells contain certain amount ofp53. Melanoma cells either completely lack or contain 
different levels of wild-type p52. When treated with genistein, these melanoma cell growths 
were significantly inhibited, and melanin content, tyrosinase activity were increased. A 
dendrite-like structure was caused to form in these cells. Transfection study showed that p53 
transfectants expressed high levels of wild-type p52 became resistant to genistein (Rauth et 
al.. 1997). 
Isoflavones bearing different structures have been associated with their different 
differentiation induction effects. Jing and Waxman (1995) studied the differentiation effects of 
isoflavones on mouse erythroleukenua (MEL) cells based on benzidine staining. Genistein. 
daidzein and genistin induced MEL differentiation, but biochanin A and apigenin had no 
effects. The potency of these chemicals on cell growth inhibition was apigenin > genistein > 
genistin > biochanin A > daidzein at assay doses from 11 to 100 nmoI/L. They concluded that 
the 4'-hydroxyl groups are essential for the differentiation induction effect, while trihydrojtyl 
derivatives are good growth inhibitors. Daidzein was considered to be a potent differentiation 
inducer with the least cytotoxic effect. Unfortunately, daidzein showed no differentiation 
effect on breast cancer cell lines MCF-7 (estrogen-receptor positive) and MDA-MB-468 
(estrogen-receptor negative) (Constantinou et al., 1998b). However, both estrogen-positive 
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and -negative cells became differentiated in response to genistein treatments, suggesting that 
the estrogen-like flmction of genistein was unrelated to the mechanism of cell differentiation. 
3. Cell cycle arrest and induction of apoptosis by isoflavones 
In most cells, the events in the nuclear cycle (spindle pole duplication and separation, 
DNA replication, spindle formation, chromosome segregation) are organized into a dependent 
sequence of steps. Any perturbation may arrest cells at a certain stage or may delay the 
transition from one stage to another. There are two important checkpoints in the cell cycle. 
One is at the Gl/S boundary. Any damage to DNA may delay the transition. Another one is 
at the G2/M boundary. DNA damage, unreplicated DNA or unassembled microtubules may 
delay progression from G2 into mitosis (Hutchison and Glover, 1995). 
Cells die primarily by one of two major mechanisms: necrosis or apoptosis. CeU death 
by necrosis occurs as a result of a marked toxic or physical insult. Programmed cell death, 
apoptosis. is a process in which individual ceUs die in a controlled manner in response to 
specific stimuli following an intrinsic program. Apoptosis characteristically affects single cells 
and is not accompanied by an inflammatory reaction. Apoptosis plays a key role in the control 
of cellular populations in development, in the immune system, and in carcinogenesis (Cohen et 
al.. 1995). 
Normal tissue homeostasis is maintained by a balance of cell input, due to cell 
proliferation and renewal, and cell death. Cancer represents an imbalance, which may be due 
to an increase in cell proliferation and/or a decrease in cell death. The induction of cancer is a 
multistep process involving tumor initiation, promotion, and progression. Apoptosis may 
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interfere with tumor formation at one or more of the steps in carcinogenic process. A defect 
in the ability of a cell with damaged DNA to undergo apoptosis may therefore lead to an 
increase in cancer incidence. Certain oncogenes and tumor suppressor genes such as c-myc, 
bcl-2 and p53 may play important roles in determining a cell's fate. Any reagent that can 
cause increased expression of c-myc and p53 and decreased bcl-2 expression in cancer cells 
will increase the possibility of cell apoptosis (Cohen et al., 1995). 
Three DNA damage-responsive cell cycle checkpoints were shown to operate in 
diploid human fibroblasts (Kaufinann, 1998). Progression firom G2 to M is controlled in part 
by cyclin-dependent kinase (cyclin B/Cdkl) that is regixlated by tyrosine phosphorylation. 
Genistein (45|imol/L) inhibits tyrosine kinase, including the one that phosphorylates Cdkl on 
Tyrl5 (Akiyama et al., 1987). This kinase is rapidly induced by treatments that trigger ceU 
cycle checkpoints and may contribute to the delay of mitosis onset. Down regulation of cyclin 
B. up regulation of the p21 WAFl growth-inhibitory protein by genistein (30 ^mol/L) were 
also seen in prostate cancer cells (Davis et al., 1998), in non-small cell cancer cell line H460 
(Lian et al.. 1998). Genistein (starting at 20 |imol/L, complete inhibition at over 80|imol/L) 
also inhibits type II DNA topoisomerase to produce a form of DNA-damage that triggers all 
of the DNA damage responsive cell cycle checkpoints (Markovits et al., 1989). 
Topoisomerase II poisons also are powerful clastogens inducing lethal and carcinogenic 
chromosomal aberrations. Type II topoisomerase can break DNA in a region of chromosome 
1 Iq23 that contains the ataxia telangiectasia gene (ATM). ATM controls all the DNA 
damage-responsive cell cycle checkpoints (Kaufinann, 1998). Thus topoisomerase poisons 
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such as genistein may trigger chromatid breakage to inactivate AT gene fiinction. disable cell 
cycle control and induce gene instability. 
Induction of p53 level may also account for an important mechanism of 
phytochemicals inducing apoptosis, as mentioned above. Non-cancerous human mammary 
epithelial 184-B5 cells were pretreated with benzopyrene (a), the altered cell proliferation was 
inhibited and apoptosis was induced by applying cruciferous glucosinolate indole-3-carbinol, 
tea polyphenol(-)epigallocatechin gallate or genistein (39 {imol/L) (Katdarc et al., 1998). 
Treating the cells with these phytochemicals resulted in a 1.8-6.9 fold increase in apoptosis. 
The induction of apoptosis was accompanied by enhanced p53 immunoreactivity within the 
cells. 
Over-expression of the bcl-2 gene makes cells resistant to apoptosis without affecting 
proliferation. At a concentration of 0.15 mM. after 24 hrs treatment, genistein inhibited the 
phosphorylation of bcl-2. The p53 level in MCF-7 cells reached a steady-state (Constantinou 
et al., 1998b). 
At different concentrations, genistein may interrupt different stages of the cell cycle. 
Spinozzi et al. (1994) added different concentrations of genistein to Jurkat T-leukemia cells. 
They found that at low concentrations (18.5-37 ^mol/L), genistein arrested cell cycle at G2/M 
phase; at higher concentrations (74-111 ^mol/L), it arrested cells in S-phase. Apoptosis 
followed m genistein-treated cells. 
Daidzein can also inhibit cell growth at cell cycle checkpoint. After stimulation by 
bombesin plus insulin for 4.6 h, Swiss 3T3 cell progression was blocked at G1 phase by 
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daidzein at concentrations over 37 ^mol/L. After removal of daidzein, insulin or insulin-like 
growth factors (IGFs) reinitiated daidzein-blocked cell cycle progression without further 
addition of bombesin. In vitro study showed that daidzein inhibited the activity of casein 
kinase II which is required for the commitment of mitogenic signal by insulin or IGF in GI 
phase (Higashi and Ogawara, 1994). 
4. Estrogenic and antiestrogenic properties of isojlavones 
Isoflavones have structural similarities to estrogen, suggesting that they may act as 
phytoestrogens. These phytoestrogens may cause beneficial or adverse hormonal effects, 
depending on the effectiveness and amount of the ingested hormone agonist, synergistic and 
antagonistic effects with other dietary or endogenous hormones, interactions with other 
dietary compounds (e.g. fiber and fat intake), and the hormone status of the individual. 
Certain cancers (breast, prostate and colon) may be hormone-dependent, such as breast cancer 
which is associated with estrogen and prolactin activity (Welsch, 1976). Estrogens bind to 
cytoplasmic receptors, and elicit their translocation to the nuclear estrogen receptor complex 
for a short time. These events initiate DNA transcription, and RNA synthesis, which in turn 
leads to protein synthesis and cell growth (Anderson, 1977). So, increasing the levels, 
intensity and duration of exposure of estrogen might increase the risk of breast cancer as well 
as other sex-hormone dependent cancers. 
The phenolic ring of isoflavones, which is a prerequisite for binding to the estrogen 
receptor, is similar in structure to mammalian estrogen l7p-estradiol. However, the 
estrogenicity of daidzein and genistein were about 10^-10^ times less than estradiol or the 
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synthetic estrogen diethylstilbestrol (DES) (Farmakalidis et aL, 1985; Kitte et al., 1980; 
Newsome and Kitte, 1980). The sheep uterine estrogen receptor binding of daidzein and 
genistein were only 0.1% and 0.9% that of 17p-estradiol, respectively (Shutt and Cox, 1972). 
Glycitein had similar estrogen receptor binding aflBnity to daidzein, but it increased female 
B6D2F1 mice uterine weight by 150% compared to control which was higher than that of 
daidzein (50% increase over control) (Song et al., 1999). Equol and 0-desmethylangolensin 
(ODMA), metabolites of daidzein, and daidzein glucuronides (CBso = 14.7 ^mol/L) and 
genistein glucuronides (CB50 = 7.27 nmol/L ) also bind to estrogen receptors and have weak 
estrogen activity (Shutt and Cox, 1972; Adlercreutz et al., 1992; Zhang et al.. 1999). Certain 
soybean foods, such as tofli and soymilk, contain comparatively large amount of isoflavones. 
After consumption, the plasma concentration of glucuronide isoflavones. isoflavone aglycones 
and other metabolites may exceed endogenous estrogens by several orders of magnitude, 
which could effectively compete with estrogen by competitive binding to estrogen receptor, 
suppressing estrogen-stimulated cell growth (Adlercreutz et al., 1995). 
Estrogen receptor (ER) is a ligand-activated transcription factor that after activation 
binds to specific DNA elements and modulates the transcription levels of target genes. Two 
Ers, ERa and ERp, have been identified. ERp was identified in 1996 (Mosselman et al., 
1996). The two receptors have some similar structures and certain properties, but also differ 
in many ways. Both receptors contain five different domains in their sequences. The N-
terminal A/B region is a transactivation domain possessing constitutive and hormone-
dependent transcription-activation function. In ER also as in many glucocorticoids receptors. 
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it is a ligand-independent transactivation domain, usually called AFl region. The C region is 
the most conserved region between different members of the steroid receptor femily, which is 
the DNA-binding domain (DBD). The D domain is regarded as a flexible hinge region 
between DBD and the E domain. E is the ligand binding domain (LED) also called AF2 
region. F is a domain of unknown function. It does not appear in all nuclear receptors, but 
does exist in ERs. Ligand binding induces a conformational change in ER and subsequent 
DNA binding to specific estrogen response elements (ERE) present in target genes. ERa has 
599 amino acids and ERp has 485 amino acids. There are about 97% and 60% amino acid 
homology in DBD and LBD respectively between these two receptors. A/B domains and 
activation function (AFl) are quite different. The AF2 core sequences are identical. ERp has 
a slightly low affinity to the ERE than ERa. Tissue distribution was slightly different in rats 
(Kuiper et ai., 1997). Kidney has only ERa. Uterus, pituitary and epididymis dominated by 
ERa. In ovary, prostate and brain, equal or greater levels of ERP have been found. As a 
weak estrogen, isoflavones may bind to these two receptors with different affinity. Makela et 
al. (1999) found that genistein bound to ERp of carotids with 20-fold higher aflSnity than to 
ERa in ovariectomized female rats. Different ligand binding affinity to these two receptors 
may contribute to the selective action of estrogens in different tissues (Kuiper et al., 1997). 
In addition to the competitive estrogen receptor binding ability, isoflavones may also 
exert their antiestrogenic effects by directly or indirectly increasing the synthesis of sex-
hormone binding globulin (SHBG), a protein that binds dihydrotestosterone, testesterone and 
estradiol. Mousavi and Adiercreutz (1993) found that at concentrations of 5-40 |aM, genistein 
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significantly increased hepatocarcinoma (Hep-G2) cell SHBG production, but suppressed the 
proliferation of these cancer cells at a stage when SHBG production continues to be high. 
The urinary excretion of the phytoestrogen equol had a positive relationship with plasma 
SHBG and negative association with plasma fi'ee estradiol, found by Adlercreutz (1987). The 
high SHBG levels in plasma will decrease hormone exposure by reducing the metabolic 
clearance rate or lowering the uptake of sex hormone in many tissues (Adlercreutz et al., 
1987; Monsavi and Adlercreutz, 1993), which in turn will decrease the risk of sex-hormone 
dependent cancers. 
Decreasing estrogen levels by isoflavones can also be achieved by inhibition of 
aromatase activity, a cytochrome P-450 enzyme that catalyzes the conversion of androgens to 
estrogens (Kellis et al., 1984; Adlercreutz et al., 1993). The competitive binding of lignans to 
aromatase with a binding aflBnity of 1/75-1/300 of natural substrates testosterone and 
androstenedione will result in a decreased substrate binding aflRnity (Adlercreutz et al, 1993). 
Urinary excretion of estradiol, estrone, estriol and total estrogens, as well as excretion of 
hypothesized genotoxic estrogen metabolites 16a-hydroxyestrone, 4-hydroxyestrone and 4-
hydroxyestradiol were decreased compared to control diet with isoflavone consumption in 12 
healthy premenopausal women (Xu et aL, 1998). This result indicated that estrogen synthesis 
can be decreased and metabolism of estrogen can be altered by isoflavone intake. However, 
isoflavones are significantly poorer inhibitors of aromatase than flavones (Kao et al., 1998). 
Several studies have examined the biological effects of isoflavones in women. 
Consumption of 45 mg/day glycosylated isoflavones in 60 g textured vegetable protein over a 
I-month period significantly (p<0.01) prolonged the length of menstrual cycle of 
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premenopausal women, and suppressed luteinizing hormone (LH) (p<0.05), and follicle-
stimulating hormone (FSH) (p<0.01) (Cassidy et aL, 1994, 1995). These findings suggested 
that soybean isoflavones may exert weak estrogenic effects on the hypothalamic-pituitary-
gonadal axis, and may be beneficial with respect to fectors stimulating breast cancer. Dietary 
soy supplementation of 84 premenopausal women with 45 mg isoflavone showed that nipple 
aspirate levels of apolipoprotein D were significantly lowered and pS2 levels raised, indicative 
of estrogenic stimulus (Hargreaves et al., 1999). Isoflavones exert weak estrogenic activities 
on postmenopausal women. Eighteen postmenopausal women consumed low- or high-
content isoflavone diet for 93 days, isoflavone significantly decreased estrogen sulfate but 
significantly increased SHBG. No estrogenic effects were observed on vaginal epithelium or 
endometrium (Duncan et al.. 1999). 
The estrogenic/antiestrogenic activities of isoflavones may also have some effects on 
other parts of the human body, such as prevention of bone loss and cardiovascular disease. 
Ishimi et al (1999) administered genistein (0.1-0.7 mg/day) or 17|}-estradiol (0.01-0.1 |ig/day) 
to sham-operated or ovariectomized (OVX) female mice for 2-4 weeks, and found that 
genistein did not reverse OVX-induced uterine atrophy, but restored B-lymphopoiesis and 
trabecular bone volume. These results indicated that genistein exhibited estrogenic action in 
bone and bone marrow to regulate B-lymphopoiesis and prevent bone loss without exhibiting 
estrogenic action in the uterus. In another study done by Draper et ai. (1997). oral intake of 
131 mg isoflavone per week had no preventive effect on bone loss of oophorectomized rats. 
Estrogen-based drug therapy in cardiovascular disease has been difficult because the 
wanted vasculoprotective effect cannot be separated fi-om the unwanted effects of the 
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hormone on the reproductive system. Isoflavones may act as drug candidates for 
cardiovascular disease prevention. Makela et al.(1999) used endothelial denudation (at 
carotid artery) in rats as their study model, and found that genistein (0.0025-2.5 mg/kg body 
weight) had a similar dose-dependent vasculoprotective effects as 17p-estradiol. Both 
genistein and 17p-estradiol were equally inhibitory to the replication and migration of smooth 
muscle cells at concentrations < 10 |iM in vitro. Treatment with 17p-estradiol but not with 
genistein caused a uterotrophic effect, which indicated that genistein was a vasculoprotective 
estrogen analog devoid of effects on the reproductive system. 
E. Immune system modulation effects of isoflavones 
In malignancy, natural killer (NK) cells appear to represent a first line of defense 
against the metastatic spread of blood-borne tumor cells, and normal NK activity may be 
important in immune stirveillance against cancer. The development and progression of cancer 
has been found to be associated with decreased natural immunity, as measured in vitro by NK 
activity and/or absolute numbers of circulating NK cells (Whiteside and Herberman, 1989). 
Many cells of the body including macrophages and neutrophils can produce prostaglandins 
(PG) (Kunkle et al.. 1984), which suppress the activation of all of the immune system: B cells 
(Thompson et al.,1984), T cells (Parhar et al., 1988). NK cells (Herman and Rabson. 1984). 
lymphokine-activated killer (LAK) cells (Parhar and Lala, 1988), as well as macrophages 
(Parhar and Lala, 1988). Tumors which produce PGE2 are able to down-regulate the immune 
system and escape lysis (Earnest et al., 1992). For the T cells, PGE: inactivation is mediated 
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by blockage of interleukin-2 (IL-2) production (Lala et al,. 1988; Chouaib et al., 1985), down-
regulation of IL-2 receptors production (Lala et al., 1988) and transferrin receptors (Chouaib 
et al., 1985). Due to the dependence ofNK cells on interferons as well as IL-2 for their 
activation, PGEj action on both of these pathways remains a strong possibility. Isoflavones as 
antioxidants can increase glutathione peroxidase activity (Hendrich et al., 1994) which inhibits 
prostaglandin production by removing the hydroperoxides required for prostaglandin synthetic 
activity (Marshall et al., 1988). So, it is possible that isoflavones may also enhance IL-2 
production and NK activity. 
NK cells kiU malignant and virus-infected cells either by Fc receptor (FcR)-dependent 
or direct cytotoxic mechanisms (Trinchieri, 1989). The FcR complex expressed on NK cells 
(FcyRIII) is a low-afi5nity receptor for the Fc fragmant of IgG and is composed of a 55- to 
70-kDa transmembrane protein (CD 16) complexed with at least two other polypeptide chains 
(Einspahr et al. 1991). Antibody-dependent cellular cytotoxicity (ADCC) is initiated by the 
stimulation of this FcR complex. Direct cell-mediated cytotoxicity is thought to be triggered 
by the interaction of an unidentified NK cell surface receptor with a putative target structure 
on malignant or virus-infected cells. In order for NK cells to become active cytolytic 
efifectors, these membrane receptor-h'gand interactions must be translated into biochemical 
signals that stimulate intracellular response systems. The suggested signals involved in the 
activation of NK cell activity including tyrosine phosphorylation, serine/threonine 
phosphorylation, phospholipase C, phospahtidylinositol and Ca"' (Chow et al., 1988; Einspahr 
et al.. 1991; Shenoy et al., 1993; Whalen et al., 1993). As the most potent activator ofNK 
cells, IL-2 activation ofNK cells is via the induction of tyrosine phosphorylation of multipie 
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proteins (Einspahr et al., 1990 and 1991). The IL-2 receptor itself lacks intrinsic tyrosine 
kinase activity (Waldman, 1991). Other non-receptor, membrane-associated tyrosine kinases, 
such as jrc-family tyrosine kinases, may associate with the IL-2 receptor and thereby relay 
information from the receptor to the cell interior. Genistein, a PTK inhibitor, like herbimycin 
A, demonstrated concentration-dependent (0.3-9 |amol/L) suppression of direct and FcR-
mediated NK cellular cytotoxicity (Einspahr et al., 1991). Therefore, the effect of isoflavones 
on NK ceU activity may depend on the balance between their inhibition of tyrosine kinase 
activity and activation of cellular cytokine production. 
An experiment performed by Drs. Cunnick and Hendrich (unpublished data) showed 
that after feeding 240 mg isoflavones /kg diet for 10 days, rat liver-associated NK cell activity 
was two-fold greater than that in the control group. However, rats receiving a dose of 480 
mg isoflavone/kg diet did not differ in NK cell activity compared with the control group. This 
study indicated that soybean isoflavone extracts can affect NK cell activity in a dose-
dependent manner. 
Exon et al. (1997) studied the effect of biochanin A on NK cell activities in vivo as 
well as in vitro. They either gavaged 8 mg/kg or intraperitoneally injected 4 mg/kg biochanin 
A into rats. Similar to control, NK cell activity was observed 29 h after treatment. When 
administered three times a week for three weeks, biochaninA did not affect NK cell response, 
antibody production or delayed-type hypersensitivity reactions. In vitro, NK ceU cytotoxicity 
was significantly enhanced in rat splenocytes exposed to 10 |imol/L of biochanin A or 
genistein. 
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Zhang et aJ. (1999a) co-cultured genistein, daidzein and genistein glucuronides with 
human peripheral blood lymphocytes at concentrations of 0.1-10 jimol/L. Genistein at 
concentrations < 0.5 jimol/L, and daidzein and genistein glucuronides at concentration of 0.1 -
10 nmol/L significantly (p < 0.05) enhanced NK cell-mediated K562 cancer cell killing. When 
used together with IL-2, genistein and the glucuronides addhively increased NK c>totoxicit>-. 
which indicated that isoflavones may function at a site different fi-om IL-2 when they activate 
NK cells. 
Other potent activators ofNK cell activity are IL-12, IL-15 and interferon gamma 
(IFN-y). IL-12 is known as an NK-stimulating factor and is a protective cytokine in infection 
involving intracellular pathogens. It works best in synergy with IL-2 to activate NK cells 
(Peakman and Vergani, 1997). The role of IL-12 in NK cells was demonstrated by culturing 
NKR-PrCD56' populations with IL-12-induced differentiation into the mature NKR-
PrCD56' stage. These cells lysed K562 tumor targets (Sivakumar et al.. 1998). This 
suggested a possible role for IL-12 in differentiation of NK cells in later stages. 
IL-15 is a differentiation fector. It shares many features with IL-2 such as the 
functional similarity of activating T and NK cells (Grabstein et al., 1994). However, these 
two cytokines differ in certain ways, like cells secreting these cytokines, sites of production, 
regulation of secretion. IL-2 is produced primarily by activated T cells, while IL-15 message 
is most aboundant in placenta, skeletal muscle, kidney, lung and heart. IL-2 secretion seems 
to be regulated at the level of transcription and message stabilization, whereas IL-15 secretion 
is controlled at different levels including translation and entry into the secretory pathway. IL-
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15 may play a major role as a differentiation factor for NK cells in certain cell line, like 
NKl.r, or inducing a more immature (CD34XDT) population of human cord blood cells 
into CD56'CD3' cells (Bennett, 1996). 
IFN-y is a major activating fector for macrophages. It can increase the metabolism, 
and phagocjtic and killing acti\Tties of macrophages. IFN-y can also induce differentiation of 
B cells and NK cells and affect T cell development. It can increase NK cell adherence to 
target cells and activate and increase the rate of target lysis. Other factors like IL-1, type I 
interferons (a and P) may play a minor but important role in enhancing NK cell cytotoxicity. 
Are isoflavones enhancing any of these cytokine secretions from other lymphocytes and thus 
affecting function of NK cells or do the isoflavones directly affect NK cells? This remains 
unkno\\'n. 
In addition to the possible efiect on NK cells, isoflavones. especially genistein, may 
have some influence on B cells and T ceils. In human B-cell lineage lymphoid cells, genistein 
inhibited multiple effects of CD-40 (in B cells function as signal transduction), namely tyrosine 
phosphorylation of several proteins, phosphoinositide turnover, and activation of 
serine/threonine protein kinase (Uckun et al.. 1991). In 1995, Uckim et al. reported that 
genistein (1.8 x 10^ cpm/nmol of'*^I-genistein), conjugated to the B-cell specific CD-19 
receptor with monoclonal antibody B43 (one molecule of genistein conjugated to one 
molecule of mAb B43 through SANPAH cross-linker), was highly effective in treating 
leukemia in a nude mouse in a model of pre-B cell human leukemia. At a concentration of 
111 |xmol/L genistein completely blocked mitogen induced T-cell receptor (TCR) c 
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phosphorylation. In the presence of the same concentration of genistein (111 ^mol/L), T-ceils 
stimulated with phytohemagglutinin (PHA) or with 0KT3, a monoclonal antibody to CD3, 
failed to undergo blast transformation (Mustelin et aL, 1990). 
When Swiss mice were fed 20 or 40 mg daidzein/kg (Zhang et al., 1997), their 
peritoneal macrophages and th>'mus weights were increased. Both humoral and cell-mediated 
immunity were enhanced. In an in vitro study, at concentrations of 0.01-10.0 fxM. daidzein 
significantly inhibited proliferation of mixed mice splenocyte cultures activated with 
concanavalin A or lipopolysaccharide in a dose-dependent manner, whereas genistein had no 
influence on the response (Wang et al.. 1997). 
There are few reports on eflfects of isoflavones on the immune system. Clearly, more 
work needs to be done on isoflavones' immunoregulatory function. 
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URINARY DISPOSITION OF SOYBEAN ISOFLAVONES DAIDZEIN, 
GENISTEIN AND GLYCITEIN DIFFERS AMONG HUMANS WITH MODERATE 
FECAL ISOFLAVONE DEGRADATION ACTIVITY'-^ 
A paper published in Journal of Nutrition, 1999, 129: 957-962 
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Abstract 
Glycitein metabolism was compared with other isoflavones, to begin to understand the 
effect of this compound. Total isoflavones of 4.5 jimol/kg body weight from soymilk (high in 
genistein and daidzein) and soygerm (high in daidzein and glycitein) were fed to 7 women and 
7 men. Only subjects with moderate fecal isoflavone degradation rates (half-
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lives of daidzein and genistein were 15.7 and 8.9 h, respectively) were included to minimize 
interindividual variation. The average 48 h urinary excretion of giycitein. daidzein and 
genistein were approximately 55%, 46% and 29% of the dose ingested, respectively, which 
were significantly different from each other in men and women {p < 0.001). Plasma isoflavone 
contents at 6 and 24 h after soymilk feeding paralleled relative amounts of isoflavones in 
soymilk (genistein > daidzein > giycitein) {p < 0.05), but plasma isoflavone contents after 
soygerm feeding did not parallel soygerm isoflavone contents in women, because genistein and 
giycitein were not different from each other at 6 h after feeding. Six hours after soygerm 
dosing, plasma isoflavone contents paralleled soygerm isoflavone contents in men. Based on 
plasma isoflavone concentrations at 6 h after dosing, the bioavailabilities of daidzein and 
genistein were similar in men and women. But at the high giycitein dose, plasma 
concentration at 24 h after dosing suggested a modest gender difference in giycitein 
bioavailability. 
Key Words: •Fecal isoflavone degradation •Giycitein •Humans •Isoflavones •Urinary 
disposition 
Introduction 
Isoflavones are one of the principal classes of plant-derived diphenols in the human 
food supply. Because the presence of isoflavones in human urine was related to lower 
mortality from sex hormone-dependent cancers, isoflavones have excited scientific researchers 
(Barnes et al., 1991). Isoflavones might be partly responsible for soy's effect to lower the risk 
of cardiovascular diseases (Anderson et al., 1995) and to prevent bone mineral loss in 
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ovariectomized rats (Aijmandi et al., 1996). Daidzein, genistein and their corresponding 
glucosides account for the major portion of soy isoflavones and have been the focus of 
numerous studies. But a third soy isoflavone, glycitein, may also contribute to soy's health 
effects. 
Systemic studies of the absorption, metabolism and excretion of isoflavones are 
needed to determine their bioavailabilities and biological effects. Among the soy isoflavones, 
a greater proportion of the dose of daidzein was excreted in urine than that of genistein (Xu et 
al., 1994; King and BursilL 1998; Watanabe et al., 1998). Watanabe et al. (1998) reported 
maximum plasma concentrations of 2.44 ± 0.65 |imoI/L at 6 h for genistein and 1.56 ± 0.34 
|amol/L at the same time for daidzein after ingestion of 103 jimol daidzein and 112 |imol 
genistein. King and Bursill (1998) reported peak of 4.09 ± 0.94 jimol/L at 8.42 ± 0.69 h for 
genistein and 3.14 ± 0.36 |amol/L at 7.42 ± 0.74 h for daidzein after 3.6 |imol genistein and 
2.7 ^mol daidzein/kg body weight soy meal ingestion. The plasma concentration/time curves 
of both daidzein and genistein were the same. Daidzein and genistein may have similar 
bioavailabilities but the longer elimination half-life of genistein may contribute to its potential 
for greater efiBcacy than daidzein. 
Glycitein and its corresponding glucosides account for 5-10% of the total isoflavones 
in most soy foods. In soygerm, glycitein accounts for at least 40% of total isoflavones. No 
biological activity or bioavailability studies of glycitein have been reported to date. Therefore, 
it is of great interest to study the bioavailability of glycitein which may be an important 
determinant of glycitein's biological potency. 
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Gut microflora may play an important role in isoflavone degradation and may be a 
critical factor in determining isoflavone bioavailability. Xu et al. (1995) showed that two 
women who excreted greater amounts of fecal isoflavones had greater urinary and plasma 
isoflavone levels than five other women who excreted small amounts of isoflavones in feces, 
and these high excrctors experienced more prolonged daidzein and genistein bioavailability. 
Gut motility and gut microflora differ among individuals. A study of gut microfloral 
metabolism of isoflavones in vitro in 15 subjects over a ten-month period showed that the 
subjects sorted into three distingtxishable groups with respect to the ability of their feces to 
degrade daidzein and genistein. Degradation rate constants for daidzein and genistein (ko and 
ko, respectively) (calculated as the negative slope of the regression line plotted for isoflavone 
content of each sample over time) were significantly different at day 0 of the study among the 
three excretor phenotypes: Low excretors (n = 5), average ko = 0.012 and ko = 0.023; 
Moderate excretors (n = 10), average ko = 0.055 and ko = 0.163; High excretors (n = 5), 
average ko = 0.299 and ko = 0.299. These phenotypes proved to be stable when reexamined 
after ten months (Hendrich et al.. 1998). These excretor phenotypes might be responsible in 
large part for the observed great interindividual variation in human bioavailability and likely 
variability in health effects of soy isoflavones. 
To study glycitein absorption and excretion patterns, male and female subjects 
possessing the moderate isoflavone degradation phenotype were chosen to minimize 
interindividual variation. A single dose of isoflavones fi:om soymilk (which contained 
predominantly equal amounts of daidzein and genistein) and soygerm (containing 
70 
approximately equal amounts of daidzein and glycitein) were provided in a well-controlled 
liquid diet. Plasma and xirine isoflavone contents were measured after feeding. 
Materials and Methods 
Experimental procedures 
Subject screening. The participants in this experiment were selected from 25 
volunteers according to their gut microfloral ability to degrade isoflavones. Freshly voided 
fecal samples from volunteers were diluted and homogenized with sterilized brain-heart 
infusion culture medium (Difco laboratories, Detroit, MI), containing 0.5 mg cysteine 
hydrochloride (Aldrich Chemical Company, Milwaukee, WI) as reducing agent and 1 mg 
resazurin (Aldrich Chemical Company, Milwaukee, WI) as O; indicator, under anaerobic 
conditions. After centrifijgation, supernatant was added to duplicate sterilized culture tubes 
containing sterilized daidzein and genistein (final concentration of each compounds: 590 
|imol/L) and incubated anaerobically at 37°C. At time 0, 6, 12, 24 and 48 h intervals, 3 mL of 
culture mixture was obtained and mixed with 0.6 mL of 100% methanol and 0.9 mL of 0.4 
moI/L trichloroacetic acid (Sigma, St. Louis, MO) containing 0.6 mol/L glycine (pH 2.0). 
Centrifiiged and filtered daidzein and genistein were analyzed by HPLC, as described below. 
The logarithm of isoflavone concentration (C) was plotted against incubation time 
intervals. The equation used was: ln(Co/C) = kt, with Co represented the initial isoflavone 
concentration and k represented the rate constant, t was the reaction time. The time needed 
for half of the isoflavone to disappear (t.^) from the culture medium was derived from the 
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equation: t., = In(2)/k. Half-lives of daidzein and genistein for participants were calculated 
(Table 2). 
Participants. Fourteen healthy subjects (seven male and seven female), with age 
between 19 and 35 years, body weight of 66.0 ± 11.2 kg, body mass index of 22.4 ± 2.3 
icg('ra", participated in this study (Table 2). The Human Subject Committee of Iowa State 
University (ISU) approved the procedures for this feeding study. Informed consent of 
subjects was obtained in writing. 
Diet. The study consisted of two breakfast feedings, which were separated by a one-
week washout period. Subjects were randomly assigned to consume either soymilk (Feain 
Natural Foods, Mequon, WI) or soygerm powders (Soylife. Schouten USA, Inc. Minneapolis. 
MN) mixed into cranberry or orange juice with an ad libitum breakfast chosen from wheat 
toast, cereals, skim milk, apple, banana or orange in a crossover design. The total amount of 
soy isoflavones fed from either soy source was 4.5 jimol/kg body weight. All subjects were 
instructed to avoid any soy food and products containing texttirized vegetable protein (TVP) 
and hydrolyzed vegetable. A list of soy-containing foods was given to subjects. 
Blood sample collection. Venous blood samples (10 mL) were collected into EDTA 
containing vacuum containers by a licensed medical technologist under stringent aseptic 
conditions. A blood sample was collected 18 h before dosing (baseline), and at 6 and 24 h 
after soy containing breakfast. Samples were centrifiiged within 1 h after collection at 3000 g 
for 25 min at 4°C (Model 4D, International Equipment Co.; Needham Hts., MA). Plasma was 
separated and stored in a -20°C freezer before analysis. 
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Urine sample collection. Each subject provided a urine sample immediately before 
dosing (time 0). After dosing, urine from each subject was pooled over the following time 
periods: 0-6, 6-12, 12-24 and 24-48 h. The total sample volume was recorded and 50 mL 
aliquots of each pooled sample were stored in a -20°C freezer until analysis. 
Analysis methods 
Soy products analysis. Two soy products, soymilk and soygerm powders were 
chosen as glycitein sources. The sample extraction and concentration determination were 
modified from the method described by Wang and Murphy (1994). Two grams of each soy 
product was extracted with 10 ml of acetonitrile and 2 mL of 0.1 N HCl for 2 h at room 
temperature. The filtered and vaporized sample was dissolved in 10 mL of 80% methanol in 
water and analyzed by HPLC. The total isoflavone content was the sum of total daidzein, 
total genistein and total glycitein (Table 1). 
Plasma and urine sample analysis. Sample preparation and analysis for plasma and 
urine isoflavones were modified from Lundh et al. (1988). One mL plasma or 5 mL urine was 
incubated with P-glucuronidase-sulfatase (Sigma chemical, St. Louis, MO) at 3TC for 20 h to 
release aglycones of isoflavones. Fifty jiL of 2,4,4'-trihydroxydeoxybenzoin (THB) (Murphy 
et al., 1997) used as internal standard was incubated together with urine samples. Incubation 
mixtures were loaded onto Extrelut® QE columns (EM Science, Gibbstown, NJ) and 
extracted with ethyl acetate. The eluent was collected and dried. The extracted plasma and 
urine isoflavones were dissolved in 2 mL of 80% methanol in water for HPLC analysis. 
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The HPLC analysis was carried out on a Hewlett Packard 1050 series s>'stem (Hewlett 
Packard Company, Scientific Instruments Di\Tsion. Palo Alto, CA). THB and the three 
aglycone isoflavones were separated and quantified on a YMC-Pack ODS-AM Cig reverse 
phase column (5 |im. 25 cm x 4.6 mm Ld.) ( YMC Inc., Wilmington, NC) attached to a 
precolunin in-line filter (0.45 ^m, AUtech, Deerfield, IL). A linear HPLC gradient was 
composed of (A) 0.1% (g/L) glacial acetic acid in water and (B) methanol. Following 20 |aL 
sample injection, solvent B was increased from 30% to 50% over 45 min, and then maintained 
at 50% for 5 min. The solvent flow rate was 1 mL/min. Analyses were monitored with PDA 
from 200 to 350 nm. Ultraviolet spectra were recorded and area responses were integrated by 
Chem Station^° software (Hewlett Packard Company, Scientific Instruments Division, Palo 
Alto, CA). Standard curves were established with a series of concentrations of each standard 
to quantify extracted daidzein, genistein and glycitein. 
Recovery study. Daidzein, genistein and THB were chemically synthesized and 
glycitein was purified in Dr. Murphy's lab at ISU. One woman's urine was coUected and used 
in this recovery study. Fifty |iL of THB and different amounts of external standards (daidzein 
10.83 to 173.20 {imol/L; genistein 10.4 to 166.46 [imol/L; glycitein 5.38 to 86.08 fimoI/L) 
were added to the urine samples. The extraction and analysis methods were the same as 
described above. Duplicates were run at each standard concentration. Recoveries for each 
compound were reported as the combined results of three repeated assays. Plasma samples 
were randomly spiked with daidzein, genistein and glycitein standards to measure recoveries 
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(0.1 g isoflavone/100 L plasma was added to each sample). Plasma and urine isoflavones 
obtained from feeding study were calculated with adjustment for recoveries. 
Statistical methods 
Analysis of variance was performed on the data obtained from this experiment with the 
SAS program (version 6.03, SAS Institute Inc. Box 8000. 1995. Gary. NO. Plasma 
concentrations of daidzein, genistein and glycitein at certain time points were analyzed 
separately and by repeated measurement analysis. Urinary excretions of the three isoflavones 
during 0-12 h after feeding were compared with the urinary excretions from 12-48 h by paired 
t-test. Data from male and female subjects were analyzed separately for both plasma and 
urine. Tukey's test was used for comparison within factors if there was significant effect. A p 
value of 0.05 or less was considered to be significant. All values are reported as means ± SD. 
Results 
Soymilk powder contained 9.0 |iimol isoflavones/g; 43.3% daidzein, 48.9% genistein 
and 7.8% glycitein, whereas soygerm powder contained 71.4 ^mol isoflavones/g; 48.5% 
daidzein, 12.6% genistein and 38.9% glycitein (Table 1). Among the selected fourteen 
subjects, the average fecal incubation half-lives of daidzein and genistein were 15.7±5.3 and 
8.9±4.3 hrs, respectively (Table 2). 
Linear regression was found in urinary recovery studies over the concentration range 
used for daidzein, genistein and glycitein (R* = 0.9984, 0.9979 and 0.9928 respectively). The 
urinary recoveries of daidzein, genistein and glycitein were: 76.4±3.5%, 85.6±3.1% and 
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61.6±4.2%, respectively. Recoveries of plasma isoflavones were: daidzein; 76.5±5.2%, 
genistein; 72.3±4.8%, and glycitein; 63.6±4.6%. 
After soymilk feeding, the plasma glycitein concentrations were significantly lower 
than daidzein and genistein, and daidzein was significantly lower than genistein {p < 0.001) at 
both 6 and 24h. At 6 h after soygerm feeding, the plasma concentration of daidzein was 
significantly higher {p < 0.001) than genistein or glycitein (Table 3). Glycitein concentration 
was significantly {p < 0.001) higher than that of genistein in male subjects but not in female 
subjects. At 24 h after soygerm feeding significantly different plasma concentrations of 
daidzein and glycitein were only found in female subjects, whereas plasma genistein 
concentration differed from neither daidzein nor glycitein. 
The two soy treatments had no significant influence on the urinary isoflavone excretion 
as a percentage of ingested doses (Table 4). Men and women had similar urinary recoveries 
after consuming these two soy products, so pooled results are presented in the table. 
Urinary excretion (as a percentage of ingested isoflavone) (Table 4) was significantly 
less {p < 0.001) for genistein than for daidzein and glycitein, and there were no differences in 
urinary excretion as percentage dose between daidzein and glycitein after 6 h. After 12 h, all 
three compounds differed significantly in their urinary excretions in the order of glycitein > 
daidzein > genistein (p < 0.001). Total excretions of the three compounds after 48 h were 
significantly different from one another (p < 0.001), just as at 12 L Interindividual variation 
in isoflavone excretion was high. Genistein excretion varied by as much as eight-fold (8.5-
69.6%), daidzein by five-fold (17.4-87.7%) and glycitein by four and half-fold (19.7-91.3%), 
among the soy product treatments. Urinary excretion of daidzein and glycitein from both soy 
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products and genistein from soyrailk product were significantly greater during the first 12 h 
than at later times {p < 0.05). 
Discussion 
Gut microflora play important roles in isoflavone metabolism and bioavailability (Xu et 
al., 1995). It is possible that the interindividual variation of isoflavone bioavailability may be 
due partly to the action of gut microflora. In order to better characterize the bioavaDability of 
isoflavones, in this study, subjects were chosen fi-om volunteers according to the ability of 
their fecal microflora to degrade isoflavones. The moderate fecal isoflavone metabolism rate 
phenotype was distinguished by the character that their fecal bacterial could rapidly degrade 
genistein with average half-lives (GVi) of 5.0 h and daidzein (D'/2) of 17 h (Wang. 1997). In 
this study, the mean fecal degradation half-lives of genistein and daidzein were 8.9 and 15.7 h 
respectively. Less fecal degradation would result in appearance of greater amount of 
isoflavones in the circulation, and greater urinary isoflavone excretion. The average urinary 
excretion of daidzein (46.4%) was nearly two-fold that of genistein (28.7%) in this study, 
which agreed with the average fecal metabolism results. However, with relatively few 
volunteers participating in the prescreening, this study included a few subjects with relatively 
long or short fecal incubation half-lives (e.g. D'/i = 21.2 h and G'/2 = 16.3 h for one subject; 
D'/s = 7.1 h and GVi = 4.1 h for another subject. Table 1). Individual urinary excretions of 
isoflavones varied widely (4.5-8 fold) even with selection of subjects by fecal degradation 
phenotype. Dietary patterns may be able to aher gut motility and fecal isoflavone degradation. 
For example, increasing insoluble dietary fibers would increase fecal bulk and decrease gut 
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transit time (Jenkins et al., 1986) and microorganism populations, which would influence 
isoflavone metabolism and absorption. In a diet controlled study, Karr et al. (1997) fed 
different levels of soy protein which contained 2.52 nmol daidzein/g protein and 4.07 (imol 
genistein/g protein to 14 subjects in four 9-day diet treatment periods. Urinary excretion of 
genistein varied by as much as 12-fold and daidzein by as much as 15-fold within diet 
treatments. In our study, except for a controlled amount of soyfoods, diet was ad libitum. 
Compared with Karr's study, the individual isoflavone urinary excretion varied within a lesser 
range. Overall, the subject screening method we used seemed to minimize the individual 
isoflavone excretion variability to some extent. Screening methods similar to ours may be 
important in understanding the role of gut microflora in phytochemical metabolism and for 
validation of the health effects of soy isoflavones and related phytochemicals. Further 
characterization of this screening technique is needed. 
Glycitein has an -OCHj group at the 6-position and neither glycitein nor daidzein have 
a 5-OH. This structural difference from genistein may result in less microflora] degradation 
than for genistein. GrifiRths and Smith (1972) reported that isoflavones and flavonoids that 
possess a hydroxyl group in the 5 position of the A-ring, such as genistein, are much more 
susceptible to C-ring cleavage by rat gut bacteria. The more isoflavones are broken down by 
bacteria, the less isoflavones would be detected in urine. This may explain why less genistein 
was recovered from urine and could also explain why genistein had a shorter half-life than 
daidzein when anaerobically incubated with fecal samples in vitro (Xu et al., 1995). Gut 
micro floral isoflavone metabolites, such as equol (Adlercreutz et al., 19820; Axelson et al., 
1982), and 0-desmethylangolensin (ODMA) (Adlercreutz et aL, 1981; Bannwart et al., 1984), 
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metabolites of daidzein; and p-ethylphenol (GrifiSth and Smith, 1972), a metabolite of 
genistein, have been identified. The metabolites of glycitein are unknown. It will be of great 
interest to develop methods to measure glycitein metabolites and to study the potential 
biological activity of both glycitein and its metabolites. 
When the molar ratio of isoflavones fed was 1.1 genistein : 1 daidzein : 0.2 glycitein 
(from soymilk. Table 1), plasma concentrations of genistein were significantly higher than that 
of daidzein, and plasma glycitein was nearly negligible. These patterns were similar to the 
soymilk feeding study of Xu et al. (1994). When soygerm (isoflavone molar ratios of 0.26 
genistein : 1 daidzein : 0.8 glycitein. Table 1) was fed, plasma glycitein concentrations were 
significantly lower than daidzein concentrations in women. But plasma glycitein and genistein 
did not differ. In men, only at 6 h after feeding soygerm did plasma isoflavones corresponded 
with soygerm isoflavone contents (daidzein > glycitein > genistein). The two plasma time 
points partially reflected dietary contents of isoflavones as well as individual metabolic 
differences. For example, subjects #10 and 11 had the highest fecal degradation half-life for 
daidzein (Table 2), and their plasma concentrations and total urinary excretions of daidzein 
after soygerm ingestion were also the largest, with 3.10 |amol/L, 60.3% (subject #10) and 
3.06 jamoI/L. 65.1% (subject #11), respectively. However, the reasons for the observed 
gender and time differences (Table 3) are unclear. Plasma pharmacokinetic studies after an 
oral dose of nearly equal amounts of genistein and daidzein fed male subjects (Watanabe et al., 
1998) showed that more genistein appeared in the circulation than did daidzein. Our soymilk 
feeding study, which had similar proportions of daidzein : genistein to Watanabe et al. (1998), 
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had similar results to theirs in both plasma and urinary excretion (Table 3 & 4). After 
soygerm feeding, genistem and giycitein plasma concentrations at 6 h (in women) and 24 h 
(both genders) did not differ, although the intake of giycitein was about 4 times that of 
genistein. If giycitein pharmacokinetics followed the same pattern as genistein and daidzein 
(Watanabe et al., 19^8, King and Bursill, 1998), lower plasma concentrations of giycitein than 
daidzein would be expected because a greater proportion of giycitein dose was found in urine 
than that of daidzein. According to retention times of the isoflavones on our reverse phase 
HPLC system, daidzein is more water-soluble than is giycitein, and giycitein is more water-
soluble than is genistein. Accordingly, daidzein would be expected to be excreted in urine 
more readily than genistein, but giycitein ought to be less readily excreted in urine than 
daidzein. Perhaps glycitein's major metabolite(s) are more water-soluble than are daidzein 
and genistein's major (glucuronide) metabolites. 
Urinary excretion of daidzein within the first 12 h was significantly greater than during 
the latter 36 h (p < 0.05). This observation agreed with Xu et al. (1994) and Tew et al. 
(1996). Giycitein showed the same excretion pattern as did daidzein. The proportion of total 
ingested daidzein, genistein and giycitein excreted in urine were the same after soygerm and 
soymilk feeding, indicating that isoflavone bioavailability was not affected by soy food type. 
This result agreed with Tew et al. (1996), who showed that after women consumed a single 
dose of 3.4 ^miol isoflavone/kg body weight as either tofii or TVP, the percentage of ingested 
genistein or daidzein excreted in urine did not differ between the isoflavone sources. 
The present study showed that the urinary disposition of three main isoflavones was 
different, with more giycitein excreted than daidzein and more daidzein excreted than 
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genisiein. A detectable amount of glychein appeared in plasma even after soymilk feeding. 
Although glycitein is a minor isoflavone, these results suggest that determining biological 
effects of glycitein would be worthwhile. 
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Table 1 
Isoflavone content of soy isoflavone sources' 
Daidzein Genistein Glycitein Total 
Soymilk (fimol/g) 3.9 4.4 0.7 9.0 
(%) 43.3 48.9 7.8 iOO.O 
Soygerm (^mol/g) 34.6 9.0 27.8 71.4 
(%) 48.5 12.6 38.9 100.0 
'Sample analysis was performed in duplicate. 
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Table 2 
Subject characteristics and fecal degradation half-lives 
No. Sex Age Weight Body mass Feeding Dn" 
y kg index (kg/m") sequence' h h 
1 M 53 8L7 25.22 B lil loT 
2 M 31 68.1 23.56 A 12.1 6.3 
3 M 22 61.3 23.95 B 21.2 16.3 
4 M 21 79.5 23.23 A 12.6 4.0 
5 M 24 61.7 20.62 A 17.7 8.3 
6 M 20 81.7 25.22 A 17.3 7.1 
7 M 19 74.9 22.37 B 13.5 6.8 
8 F 21 56.8 18.98 A* 15.2 5.4 
9 F 35 65.8 25.70 B 5.7 5.6 
10 F 23 80.4 24.27 A 23.2 12.3 
11 F 32 49.9 21.60 A 22.5 13.6 
12 F 20 56.8 20.13 B 7.1 4.1 
13 F 31 62.2 22.85 B 20.2 16.8 
14 F 33 49.9 9.49 B 15.3 8.0 
Mean 26.1 66.0 22.4 15.7 8.9 
SD 5.98 11.2 2.3 5.3 4.3 
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Table 2 (continued) 
'Feeding sequence means which soy product was taken first. A = soymilk intake first; B = 
soygerm intake first. There was a one-week washout period between each feeding. 
"This person did not finish her sojinilk. Sample was not collected. 
^Daidzein and genistein degradation half-life by gut microflora. 
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Table 3 
Plasma concentration of isqflavones in humans after a single dose of 4.5 fonol total 
isoflavones/kg body weight from soymilk or soygerm' 
Oh 
Female 
6h 24h Oh 
Male 
6h 24h 
|imol/L 
Soymilk powder 
Daictein ND 1.04^0.61" 0.20±0.1l'' ND I.29±0.5& 0.20±0.05^ 
Genistein ND 1.70±1.01' 0.39±0.28'' ND l.78±0.83' 0.54±0.35'' 
Glycitein ND OJOdO.OS" ND" ND 0.2 2 ±0.08" NDF 
Soygerm powder 
Daidzein ND 1.63±1.03^ 0.22±0.15^ ND 1.16±0.44'' 0.24±0.04'"^ 
Genistein ND 0.5l±0.l9^ 0.16±0.12^ ND 0.47±0.29^ 0.19±0.07'^ 
Glycitein ND 0.73±0.22^ 0.08±0.07^ ND 0.85±0.25^ 0.29±0.08'' 
'Values are means ± SD. n = 6 for female soymilk feeding and n = 7 for male soymilk and 
both male and female soygerm feeding. ND = not detectable, at a detection limit of 0.05 
|amol/L injected. 
"Plasma samples from soymilk and soygerm were statistically analyzed separately. Values in a 
column with different superscripts are significantly different (p < 0.05). 
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Table 4 
Human urinary isoflavone excretion as a percentage of dose ingested after a single dose of 
4.5 fjmol total isoflavones/kg body weightfrom soymilk vs soygerm' 
Time intsr\'al after dosing 
0-6 h 6-12 h 12-24 h 24-48 h Total 
% ingested dose 
Soymilk 
Daidzein"^ 14.2111.5" 20.5110.4" 10.717.9 3.213.5 48.6123.1" 
Genistein"'^ 6.315.4" 9.5l6.r 9.018.0 2.813.6 27.6120.7' 
Glycitein""^ 12.5110.0" 28.0115.4" 11.818.3 3.012.6 55.3126.0 
Soygerm 
Daidzein"'^ 13.211 i.r 14.717.3" 12.019.6 3.914.1 43.8113.7" 
Genistein""^ 5.114.2" 6.714.8' 14.1113.3 3.814.1 29.7117.8' 
Glycitein'"^ 17.6115.6" 19.9112.0" 14.8113.1 2.212.2 54.5117.2" 
'Values are means ± SD. For soygerm intake results, n = 14; for soymilk intake results, n = 
13. 
'The amount of each isoflavone compound intake was considered as 100%. 
^Values in a column with different superscripts are significantly different (p < 0.05). 
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Erratum 
The soybean isoflavone content was calculated according to their extinction 
coefiBcients and normalized to the total daidzein, genistein and glycitein calculated as aglycone 
isoflavones. Due to re-purification or recent commercial availability, the extinction 
coeflScients of acetylgenistein and acetyldaidzein were re-studied. The new extinction 
coefficients for these two compounds were 38946 and 29007, respectively. 
According to these new data, the isoflavone contents of the soygerm and soymilk used 
in this feeding study were over-estimated previously. The recalculated isoflavone contents in 
both soy milk and soygerm powders are shown in Tablet. 
Urinary isoflavone excretion as a percentage of ingested dose were modified 
accordingly. Because there was difference in urinary excretion as percentage of ingested dose 
according to the soy food administred, combined data are shown in Table 2. Total urinary 
excretion of daidzein (52.4%) was slightly greater than that of glycitein (46.7%), but there 
was no significant {p = 0.08) difference between them. Both daidzein and glycitein excretion 
were significantly greater than that of genistein (37.0%) (p = 0.0004 and p = 0.01 
respectively). 
Female subjects excreted a sUght greater amount of all three compounds at each time 
points than did male subjects {p = 0.03). The overall urinary excretion as percentage of 
ingested dose (total over 48 h) of daidzein, genistein and glycitein were 57.4,42.3 and 50.2% 
in female, and 48.8, 36.4,42.1% in male, respectively. 
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Based on these new data, the urinary disposition of the three main isoflavones were 
more daidzein and glycitein excreted than genistein, and daidzein and glycitein had similar 
excretion. This disposition pattern was different from that reported previously (glycitein 
greater than daidzein, Zhang et al., 1999). On reverse phase HPLC analysis, daidzein and 
glycitcin appeared earlier than genistein by more than 5 min, and glycitein was elated about 1 
min later than was daidzein. These HPLC results suggested that daidzein and glycitein had 
similar hydrobicity and they were more hydrophilic than was genistein. The absence of 5-OH 
group makes both daidzein and glycitein more hydrophilic. The 5-OH forms part of an 
internal hydrogen bond that makes genistein more hydrophobic although it contains more free 
hydroxyl than glycitein or daidzein. The absence of the 5-OH probably makes daidzein and 
glycitein less susceptible to microbial breakdown than is genistein (GrifiBths and Smith, 1972). 
The new calculated data urinary disposition of isoflavones fit well with their observation 
structural properties. 
Little study has been done comparing isoflavone bioavailabilty between genders. 
Lampe et al. (1998) fed people with soy protein containing 22 mg daidzein and 8 mg genistein 
for 4 days. They did not find any differences in daily excretion of daidzein, genistein and O-
desmethylangolensin between equol excreters and nonexcreters and between men and women. 
The slight gender differences in isoflavone urinary excretion observed in this study need 
fiirther study. 
Overall, re-calculation showed that daidzein and glycitein had similar bioavailability 
and they were more bioavailable than genistein, based on urinary disposition. 
90 
Lampe JW., Karr SC., Hutchins AM and Slavin JL. (1998) Urinary equol excretion with a 
soy challenge : influence of habitual diet. Proc. Soc. Exp. Biol. Med. 217(3): 335-339. 
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Table 1 
Isoflavone content of soy isoflavone sources' 
Daidzein Genistein Glychein Total 
Soymilk (|imol/g) 3.3 3.7 0.7 9.0 
(%) 42.9 48.1 9.0 100.0 
Soygerm (|j.mol/g) 23.1 4.5 27.8 71.4 
(%) 41.7 8.1 50.2 100.0 
'Sample analysis was performed in duplicate. 
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Table 2 
Human urinary isqflavone excretion as a percentage of dose ingested after a single dose of 
4.5 ijmol total isoflavones/kg body weightfrom soy' 
Time inter/al after dosing 
0-6 h 6-12 h 12-24 h 24-48 h Total 
% ingested dose 
Daidzein-^ 15.9±11.6'' 20.0±9.5' 12.1±9.8 4.3±4.2 52.4±19.6" 
Genistein--^ 7.916.0" 10.816.8" 13.0±16.9 5.3±5.4 37.0125.9" 
Glycitein--^ 13.5110.5' 18.7112.0" 10.718.7 3.712.0 46.7118.1' 
'Values are means 1SD. There was no soy type differences in urinary excretion. A combined 
data from soymilk and soy germ is presented in this table. 
"The amount of each isoflavone compound intake was considered as 100%. 
Values in a column with different superscripts are significantly different (p < 0.05). 
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GLUCURONTOES ARE THE MAIN ISOFLAVONE METABOLITES IN WOMEN 
FED SOY MILK POWDER 
A paper to be submitted to the Journal of Nutrition 
Yan Zhang', Suzanne Hendrich'*^ and Patricia A. Murphy' 
Abstract 
Three experiments were conducted to characterize metabolism of isoflavone from 
soymilk in women: two meals in two weeks separated by a one-week washout, one meal 
feeding, and six consecutive days of feeding. Urine and plasma samples were extracted 
directly or pre-digested before extraction with either P-glucuronidase/sulfatase (H-2 type) to 
obtain total isoflavones or P-glucuronidase (B-3 type) to eliminate isoflavones that came 
from sulfate forms. The percentages of glucuronide and aglycone isoflavones were 
calculated. Among the three experiments, no significant differences were found in the 
proportion of glucuronide and aglycone isoflavones recovered from plasma or urine. The 
percentages of daidzein and genistein glucuronides were 76.8±7.5 and 70.9±8.4% of total 
daidzein and genistein excreted from urine, and 59.4±9.5 and 50.9±9.5% of total daidzein 
and genistein presented in plasma, respectively. Percentages of aglycone daidzein and 
genistein were 4.8±2.9 and 5.7±3.6% of total daidzein and genistein in urine, 19.6±4.9 and 
21.2±7.6% of total daidzein and genistein present in plasma, respectively. With six-day 
'Department of Food Science and Human Nutrition, Iowa State University. Ames, IA 50011 
"Corresponding author. Fax:515-294-6193. E-mail: shendric@iastate.edu. 
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continuous feeding, total urinary excretion at day 5 and 6 respectively were 54.3±11.9 and 
48.3±7.6% of daidzein ingested, and 23.7±17.0 and 20.1±9.7% of genistein ingested. The p 
value between these two days was 0.12. These studies show that significant amounts of 
aglycone isoflavones circulate in the human body. But because the glucuronide isoflavones 
predominate in vivo, these metabolites might contribute to observed effects of isoflavones. 
Key words: glucuronide • aglycone • isoflavone • proportion • feeding protocol 
Introduction 
Since the detection and identification of isoflavonoids in animal and human diets and 
body fluids, many studies on their biological roles in health and disease have been carried 
out. The isoflavones daidzein, genistein, glycitein, formononetin, and biochanin A possess 
estrogenic/anti-estrogenic activities, which may affect hormone production and metabolism 
as well as cancer cell growth by a number of mechanisms that make them candidates for a 
protective role with special regard to sex hormone dependent cancers. 
Upon ingestion, glycosides of isoflavones may undergo acidic and enzymatic 
hydrolysis in the intestine. Free aglycone isoflavones undergo further reactions by gut 
microflora. The metabolism of isoflavones has been of interest, because their metabolites 
may contribute to observed effects of ingested isoflavones. In the 1950s, the metabolites, 
equol from daidzein, and daidzein from formononetin have been attributed as the major 
causes of infertility syndrome among sheep grazing on subterranean clover. The metabolite 
of genistein, p-ethylphenol, has been considered as a biologically less active compound than 
is genistein (Shutt, 1976). Both daidzein and genistein are active compounds. Daidzein was 
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reportedly able to enhance mitogen-stimulated activation of murine lymphocytes in 
physiologically relevant concentrations of 0.01-10.00 ^M, and to enhance mouse immune 
functions at a dose of 20 or 40 mg/kg body weight, but genistein foiled to do that (Zhang et 
al., 1997 and Wang et al., 1997). Genistein is a specific inhibitor of protein tyrosine kinases, 
topoisomerase II and histidine protein kinase. Tyrosine kinases appear to play an important 
role in cell proliferation and transformation. They are correlated with the ability of 
retroviruses to transform cells, and are also associated with expression of breast cancer 
oncogenes (Herman et al., 1995). The protein kinase inhibition ability of genistein may 
explain its cancer prevention effects. Arora et al. (1998) reported that the possible 
metabolites of daidzein and genistein, 4 and 5-hydroxy derivatives of equol (4' 7-
dihydroxyisoflavan), were more potent antioxidants than daidzein and genistein in inhibition 
of lipid peroxidation in a liposomal system. It is possible that in biological systems, many 
beneficial effects exerted by soy isoflavone consumption may come from the combined 
effects of isoflavones and their metabolites. It is worthwhile to study all the metabolites to 
help us fully understand isoflavone activities and mechanisms of effects. 
After absorption, the predominant forms of isoflavones in human urine and plasma 
are their glucuronide. sulfate, and sulfoglucuronide conjugates (Adlercreutz et al., 1993 & 
1995, Yasuda et al., 1994). The aglycone forms are biologically active, as reported by many 
studies. The activity of both sulfate and glucuronide conjugates are not well studied. The 
glucuronides may possess biological activity. Weak estrogenic and human natural killer cell 
activation activities of daidzein and genistein glucuronides at range of 0.1-10 jimol/L were 
noted in vitro (Zhang et al., 1999a). Peterson et al. (1998) detected genistein 7-sulfate in 
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human breast cancer cell lines after incubation with [4-''*C]genistein. But the hydroxylated 
and methylated metabolites, not the sulfate form, were considered as the active forms of 
genistein in these cancer cell lines. The conjugates might be deconjugated by the target 
organ to the active free forms, as with deconjugation of estradiol- and estrone-3P-D-
glucuronides demonstrated in Syrian hamster kidney and liver lysosomes and microsomes 
(Zhu et al., 1996). 
Conjugations are considered to be the major detoxification system and glucuronides 
are the major portion of isoflavones in plasma and urine (Lundh, 1995). Doerge et al (2000) 
found that several UDP-glucuronyltransferase isoforms catalyze 7- and 4'-glucuronides of 
isoflavone formation, but the lAlO isoform from human colon microsomes was specific for 
genistein. and equal activity was found for daidzein in human liver and kidney microsomes. 
Even with this detailed study, the distribution of glucuronide, sulfate and free isoflavones in 
biological systems has not been well characterized. By labeling with '"'C, Sfakianos et al. 
(1997) infused genistein into duodenum and recovered 70-75% of the dose from bile as 7-0-
(3 glucuronide conjugate. Recently, by feeding one man with a single dose of soy protein 
isolate. Cimino et al. (1999) reported that about 86% of genistein and 75% of daidzein 
appearing in urine were glucuronides. In comparison, only 28% of genistein as glucuronide 
and 18% of daidzein as glucuronide were found in Sprague Dawley rats. The aglycones 
daidzein and genistein were less than 1% of total isoflavones recovered in urine, but over 
20% of both compounds recovered from rat urine. On the other hand, in their feeding study. 
Holder et al. (1999) reported that over 90% of the isoflavones appearing in the blood after 
Sprague Dawley rats received 0.5-1250 |ag genistein/g of chow were genistein glucuronides. 
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Lundh (1995) reported that the total amount of unconjugated isoflavones in plasma were less 
than 5% at any time in cows and sheep, with free equol constituting about 5% in cows and 
1% in sheep, and daidzein concentrations at around detection Umit. No studies have been 
reported regarding glucuronide distributions in women. In order to probe mechanisms of 
isoflavone action in vivo, isoflavone metabolism, pharmacokinetics and bioavailability 
should be understood 
To investigate the proportion of glucuronide and aglycone isoflavones in both plasma 
and urine after soy consumption, healthy women were fed 25 g soy milk powder at breakfest. 
Also, three different feeding protocols were used to study isoflavone absorption and 
excretion patterns. 
Materials and methods 
Three feeding studies were performed. Six healthy female subjects were recruited for 
the first study. This study consisted of two breakfast meals, which were separated by a 1-wk 
washout period. Subjects were instructed not to take any foods except the soymilk for 
breakfast, and to eat nothing before blood was drawn 3 hrs after breakfast. In the second 
(single meal) and third (six meals) studies, five healthy female subjects participated in each 
study. The same amount of soymilk (25 g/person) was provided, but bread, milk, bananas, 
apples and raspberry jelly were also available to them in the latter two studies. Subjects ate 
whatever they wanted except for avoiding soy foods or foods containing textured vegetable 
protein and hydrolyzed vegetables protein for at least two days prior to the study. The 
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Human Subjects Committee of Iowa State University (ISU) approved the procedures for 
these feeding studies. Informed consent of subjects was obtained in writing. 
Soymilk powder was purchased from a local grocery store (Now Foods, Glendale, 
IL). Isoflavone content was extracted and analyzed by HPLC in Dr. Patricia A. Murphy's 
laboratory at ISU, with total of 0.82 mg/g soy of daidzein and 0.97 mg/g of genistein on 
aglycone basis (Wang and Murphy, 1994). 
Venous blood samples were collected into EDTA-containing vacuum containers by a 
licensed medical technologist under stringent aseptic conditions. Blood samples of 10, 25 
and 25 mL were collected at 3 h for the first, second and third study, respectively. After 
dosing, urine was collected over 24 hrs from each subject for the first and second study. For 
the third study, urine was collected for 24 hrs over each of days 5, 6, and 7. The treatment of 
blood and urine samples was the same as described by Zhang et al. (1999b). 
Total daidzein and genistein concentrations in plasma and urine samples were 
analyzed by using P-glucuronidase/sulfatase H-2 type (EC 3.2. 1.31. from Helix pomatia, 
Sigma Chemicals) as the deconjugation enzyme. To investigate the amount of isoflavone 
glucuronide alone, p-glucuronidase B-3 type (EC 3. 2. 1.31, from bovine liver, Sigma 
Chemicals), which does not contain any detectable sulfatase activity, was used. The units 
from B-3 type were adjusted to match the units of glucuronidase in H-2 type. Enzyme of 
5.000 units per sample was used for urine analysis and 2,000 units per sample for plasma 
analysis. A preliminary analysis with greater amount of enzyme at 7,000 or 100,000 units 
per sample were tested on urine samples and 5,000 units for plasma samples in order to make 
sxure the reaction was complete with the amount we selected. The preparation, extraction and 
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HPLC methods were the same for both enzyme treatntents and were the same as stated in 
Zhang et al. (1999b). 
For the study of free isoflavone concentration in plasma and urine without any 
deconjugation, 3 mL samples were mixed with 1.5 mL 1.5 mol/L sodium acetate buffer (pH 
= 5.5). internal standard 2, 4.4'-trihydroxydeoxybenzoin (THB) and injected into pre-wet 
Cig Sep-Pak (Minipore Co., Bedford, MA). After washing with 2 mL 0.15 mol/L sodium 
acetate buffer (pH = 3), plasma free isoflavones were eluted with 4 mL methanol dried under 
Ni and further dissolved with 0.25 mL 80% methanol in water, while urine free isoflavones 
were washed out with 2 mL 80% methanol in water. 
The percentages of daidzein and genistein that come from glucuronidation alone were 
calculated by the following formula: (IB3 -IFr)/IH2 x 100. IB3 represented isoflavone came 
from B3 type enzyme hydrolysis. IFr represented free isoflavone without hydrolysis. IH2 
represented isoflavone came from H2 type enzyme hydrolysis. The percentages of sulfate 
isoflavones were calculated as: (IH2-IB3)/IH2 x 100. 
Statistical analysis was applied with the SAS program (version 6.03, SAS institute, 
1995 Gary, NC). Total isoflavones and aglycones in both plasma and urine were analyzed 
separately. When three studies were analyzed together, each study was treated as a block. 
The differences between urine and plasma glucuronide percentage were compared by paired 
t-test. A P value of 0.05 or less was considered to be significant. 
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Results 
In the two-meal feeding study, results were collapsed across feeding, so urinary and 
plasma results from both feedings were combined among subjects. The urinary excretion of 
isoflavones over 24 h after soy milk ingestion is shown in Table 1. There were no 
significant differences (p = 0.13) in total isoflavone excretion between 24 h urine samples 
analyzed from two-meal and one-meal studies and on days 5 and 6 in the six-meal study. All 
of these 24 h samples contained significantly {p < 0.05) more isoflavones than did the sample 
collected on day 7 in the six-meal study. No significant differences of urinary isoflavone 
excretion (p = 0.12) were found between day 5 and day 6 in the six-meal study. With 
soymilk intake at breakfast, the average total excretion of daidzein (Daid-Hj) and genistein 
(Gein-Hi) was 58.2±11.5% and 22.3+11.6% of ingested doses, respectively, which were 
significantly (p < 0.001) different between these two compounds. Aglycone isoflavones 
were also detected in the samples. No significant differences in urinary aglycone excretion 
were found among the three studies. Total aglycone daidzein and genistein excreted in 24 h 
urine samples when soymilk was fed at breakfast were 2.5±0.9 and 1.2±0.6% of ingested 
dose, respectively. 
The plasma concentrations of total daidzein (Daid-Hi) and genistein (Gein-H2) were 
significantly {p < 0.05) greater in the two-meal study than in the other two studies (Table 2). 
No significant differences in plasma concentrations were found between day 5 and day 6 in 
the six-meal study and between the one-meal and six-meal studies. In all three studies, 
significant {p < 0.001) differences were found between daidzein and genistein. In the two-
meal study, the total amount of plasma obtained was not enough for aglycone isoflavone 
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analysis by our method. In the one-meal and six-meal studies, we were able to analyze 
aglycone isoflavone content with increased blood volume. Again, no significant differences 
were found between plasma taken on day 5 and day 6 in the six-meal study and between the 
one-meal and six-meal studies, and the amounts of daidzein and genistein found were 
significantly different (p < 0.001). The average plasma aglycone daidzein and genistein 
concentrations were 0.47±0.09 and 0.11±0.05 fiM, respectively. 
The percentage of isoflavone glucuronide was calculated by deducting isoflavone 
measured without enzyme digestion from that obtained after B3 enzyme digestion. The 
amount obtained from this calculation was divided by that seen after Hi digestion and then 
multiplied by 100. With no significant differences among the three studies, percentages of 
urine glucuronide or aglycone isoflavone were combined (Fig. 1). For plasma, only the one-
meal and six-meal study results were combined. In both plasma and urine, percentage of 
daidzein glucuronides (DGs, 64.2 and 73.4% respectively) were significantly (p < O.OI) 
greater than that of genistein glucurom'des (GGs, 53.4 and 69.1% respectively). The 
percentage of aglycone genistein (25.6%) was significantly (p < 0.05) greater than that of 
aglycone daidzein (19.4%) in plasma, but not in urine (4.1 and 4.5%, respectively). 
Comparing plasma to urine results, the percentages of both DO and GO in plasma were 
significantly {p < 0.05) less than in urine, but the percentages of aglycone daidzein and 
genistein were the counterpart. 
Dihydrodaidzein and dihydrogenistein were detected in urine only as minor 
metabolites (Fig. 2). Equol was only detected in one subject's urine in the six-meal study 
and also as a minor metabolite. 
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Discussion 
In humans, the majorities of isoflavones circulate and are excreted in urine as the 
glucuronide conjugates, with a much lower percentage existing as other forms. Our study 
ftulher confirmed this view. The percentages of DG and GG of total urinary isoflavones in 
our urine samples from female subjects detected by LC-UV system were slightly lower than 
that (75 and 86%) detected by Cimino et aL (1999) in the male subject by LC-MS system. 
However, in the same paper, Cimino et al. (1999) detected 52 and 26 % of genistein and 
genistein sulfate, respectively, in their female Sprague-Dawley rat urine. Holder et al. (1999) 
detected over 90% of genistein glucuronide of total isoflavones in the blood in both male and 
female Sprague-Dawley rat blood by their LC/ES-MS systenx Unfortunately. Cimino et al. 
(1999) did not report any blood concentrations and Holder et al. (1999) did not report any 
urine excretion results in their studies. However, based on our study results, blood and urine 
showed similar proportion of glucuronide vs aglycone isoflavones. Our glucuronidation 
results and calculated daidzein and genistein sulfates were in the same range as reported by 
Cimino et al. (1999), as stated above. Holder et al. (1999) did not report any differences in 
glucuronidation in both male and female rats. These results probably indicated that there was 
not too much gender difference in isoflavone biotransformation. However, we have to notice 
the significantly different results obtained by using the same rat strains (Cimino et al., 1999: 
Holder et al., 1999). Different extraction and analysis methods have been applied by 
different researchers. In order to fully understand isoflavone metabolism, standard study 
methods seem to be crucial. 
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In addition to the conjugated isoflavones and isoflavone agiycones, we also detected 
dihydrodaidzein and dihydrogenistein in every participant in our study (Fig. 2). Heinonen et 
al. (1999) detected both compounds in all the subjects when they fed them three soy bars per 
day for 2 weeks, and they claimed that dihydrodaidzein was the main metabolite of daidzein 
and dihydrogenistein was the major metabolites of genistein. Kelly et al (1993) identified 
dihydrogenistein as a minor metabolite of genistein in urine in only one of 12 subjects after 
40 g soy flour challenging for 2 consecutive days. In our study, both dihydrodaidzein and 
dihydrogenistein appeared as minor metabolites of daidzein and genistein, respectively. 
These metabolites appeared in the urine after a single feeding as well as during six 
consecutive days of feeding. The highest amount observed in all the studies was < 0.3 and 
0.1 |imol/L for dihydrodaidzein and dihydrogenistein, respectively. Apparently, the 
formation of dihydrodaidzein and dihydrogenistein were different from equol. Equol 
appeared after repeated isoflavone feeding as an adaptive metabolite from gut microflora. 
Feeding length did not make any difference for the appearance of both dihydrodaidzein and 
dihydrogenistein in the current study. The difference that may explain the different results 
(dihydroisoflavones as minor or major metabolite) observed by three different researchers 
may be the population of gut microflora. As we noticed, these three studies were performed 
in three different countries (Australia, Kelly et al, 1993; Finland. Heinonen et al, 1999: and 
USA. current study, 2000). Likely isoflavone metabolism varies among people in different 
regions. However, no direct evidence is available at this time. 
In our six-meal feeding study, we did not see any significant differences in both urine 
isoflavone excretion and 3 h plasma isoflavone concentrations between day 5 and day 6. Xu 
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(1994) also observed that urinary excretion of isoflavones at day 6 and day 7 of continuous 
soymilk feeding were similar. With prolonged feeding, a consistent midterm could be 
observed for isoflavone absorption and excretion. We observed that two out of five persons 
continuously excreted relatively greater proportion of isoflavones from urine in day 7 than 
the rest. Also we did not see any differences in urinary excretion and plasma concentrations 
of isoflavones from these three feeding protocols, which indicated that body isoflavones 
metabolism was not affected by the minor differences in the 3 protocols used. 
We noticed that in our two-meal feeding study a greater plasma isoflavone 
concentrations was seen than in the one-meal and six-meal studies. The possible reason may 
be due to the feeding protocol. Subjects were limited to soymilk only at breakfast before the 
3 h blood samples in the two-meal study, but had free access to breakfast foods along with 
soymilk in the one-meal and six-meal studies. As the only available energy source, soymilk 
may be digested fast and more isoflavones would enter the circulation system earlier. 
However, comparing 24 h urine excretion, there were no significant differences among the 
three studies. Either the food consumption after 3 h blood sampling in the two-meal study 
slowed down isoflavone excretion, or food consumption limited isoflavone conjugation and 
excretion. The metabolism of isoflavones by gut microflora seemingly was not influenced by 
meal intake patterns, which needs to be further studied. 
The soy milk powder we used contained slightly higher genistein (0.97 mg/g soy) 
than daidzein (0.82 mg/g soy). In our previous study (Zhang et al.. 1999b). at 6 h after a soy 
containing meal the plasma isoflavone concentrations paralleled the concentrations in the soy 
foods with genistein concentration higher than that of daidzein. Also, during in vitro 
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synthesis of isoflavone giucuronides (Zhang et al., 1999a), genistein was a better substrate 
for the UDP-glucuronyltransferase en2yme than was daidzein. Watanabe et al. (1998) also 
found that plasma concentration of daidzein was always (72 hrs continuous measurement) 
lower than that of genistein with their 60 g kinako (103 pimol daidzein and 112 |imol 
genistein) feeding. There is no evidence that biotransformation activity will dramatically 
change over the course of a day given normal dietary conditions. We assximed that in our 
feeding studies the plasma concentrations of genistein at 3 hrs should be higher than that of 
daidzein, paralleling food content of each isoflavone. But genistein concentrations were 
lower than daidzein in all three studies. This plasma result paralleled the urine excretion 
pattern over 24 h (the time course for near total elimination of a single isoflavones dose). 
Thus either urinary isoflavone excretion or 3 h plasma isoflavone concentrations may be a 
good reflection of overall isoflavone bioavailability. In the present study, perhaps we 
captured data that more accurately reflected peak isoflavone concentration in plasma by 
sampling at 3 h rather than the 6 h time point used in earlier isoflavone bioavailability 
studies. 
Isoflavones can be rapidly glucuronidated in the gastrointestinal mucosa in rats, as 
shown by Sfakianos et al. (1997) with genistein as the model compared. The proportion of 
both glucuronide and isoflavone aglycones in plasma significantly differed from urine in the 
current studies, with relatively greater percentages of aglycone but lower giucuronides found 
in plasma than in urine, which indicated that other tissues are also important 
biotransformation sites for isoflavones. 
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In this study, with three different feeding protocols, we demonstrated that the body 
metabolizes isoflavones relatively consistently. Glucvironides are the predominant 
metabolites of isoflavones. Given our previous findings of biological effects of isoflavone 
glucuronides, these metabolites deserve further study with report to mechanisms of 
cholesterol lowering (Potter et al.. 1998). anticancer (Barnes et al., 1994) and 
antiosteroporotic effects (Messina and Messina, 2000) of isoflavones. However. 
considerable amounts of aglycone isoflavones appeared in blood as well. In studying 
biological effects of isoflavones, nutritionally relevant concentrations of isoflavones and their 
major metabolites should be considered. 
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Table 1 
Percentages (%) of isqflavones excreted from 24 h pooled human urine after ingestion of 
25 g soymilk powder* 
Two meals One meal Six meals 
day5 day6 day7 
Measiired daidzien 
'Daid-H2 
-Daid-Bs 
^Daid-free 
66.4±11.1* 
46.4±7.1" 
2.410.8' 
62.016.8" 
48.517.0" 
2.610.6" 
54.3111.8" 
44.5112.2" 
2.511.4" 
48.317.5" 
37.614.8" 
2.711.5" 
11.417.5" 
9.315.3" 
0.7+0.4" 
Calculated daidzein 
Daid-glucuronide 
Daid-sulfate 
44.016.4 
18.316.3 
45.915.2 
13.614.5 
42.0111.6 
9.812.6 
34.915.6 
10.713.2 
8.714.9 
2.112.6 
Measured genistein 
'Gein-H2 
'Gein-Bs 
""Gein-free 
27.3110.3" 
19.317.7" 
1.110.5" 
18.1110.4" 
13.318.0" 
0.810.4" 
23.7116.9" 
17.1113.3" 
1.311.0" 
20.119.7" 
16.318.1" 
1.010.5" 
5.315.9" 
3.813.7" 
0.210.2" 
Calculated genistein 
Gein-glucuronide 
Gein-sulfate 
18.215.3 
7.714.6 
12.516.8 
4.812.5 
17.0113.3 
5.413.9 
15.318.0 
3.911.9 
3.513.6 
1.512.2 
*. Letters with different superscripts within the same row indicate the significant differences 
at /? = 0.05 value. The two compounds daidzein and genistein were significantly {p = 0.001) 
different from each other at all points. N = 6, 5 and 5 for each study, respectively. 
1. H-2 type p-glucuronidase/sulfatase was used as the deconjugation enzyme. 
2. B-3 type (J-glucuronidase was used as the deconjugation enzyme. 
3. E.xtracted directly without using any deconjugation enzyme. 
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Table 2 
Plasma isoflavone concentrations at 3 h after 25gsoymilk consumption* 
Two meals One meal Six meals 
day 5 day 6 
Measured daidzein 
'Daid-H2 
-Daid-B3 
^Daid-free 
5.410.5" 
4.710.6" 
|imol/L 
2.910.3' 
2.510.3" 
0.510.1 
2.310.6' 
1.910.5' 
0.510.1 
2.310.5' 
1.810.3' 
0.410.0 
Calculated daidzein 
Daid-glucuronide 
Daid-sulfate 0.7±0.2 
1.910.3 
0.410.1 
1.510.5 
0.410.2 
1.410.3 
0.610.3 
Measured genistein 
'Gein-H2 
*Gein-B3 
^Gein-free 
1.110.4" 
0.810.3" 
0.610.2' 
0.510.1" 
0.210.1 
0.510.2' 
0.410.1' 
0.110.0 
0.410.1' 
0.3+0.0' 
0.110.1 
Calculated genistein 
Gein-glucuronide 
Gein-sulfate 0.310.1 
0.310.1 
0.110.0 
0.310.1 
0.110.1 
0.210.1 
0.110.0 
*. Letters with different superscripts within the same row indicate the significant differences 
at p = 0.05 value. The two compounds daidzein and genistein were significantly {p = 0.001) 
different from each other at all points. 
1. H-2 type p-glucuronidase/sulfatase was used as the deconjugation enzyme. 
2. B-3 type P-glucuronidase was used as the deconjugation enzyme. 
3. Extracted directly without using any deconjugation enzyme. 
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• aglycone 
• Sui^e 
S Glucuronide 
Figure 1: Percentages of conjugates and aglycone isoflavones in both urine and plasma. 
Samples were analyzed with selective enzymes of P-glucuronidase/sulfatase (H2 type) or p* 
glucuronidase (B3 type). Free aglycone isoflavones were analyzed without using any 
hydrolysis enzyme. Glucuronide was calculated by (B3 type-Free)x IOO/H2 type. Sulfate was 
estimated by H2 type-Bs type-Free. The percentage of glucuronide form of both daidzein and 
genistein in urine were significantly {p = 0.05 and 0.001 respectively) higher tlian in plasma. 
The percentage of aglycone daidzein and genistein in plasma were significantly (p = 0.001) 
higher than in urine. 
Dein 
Gein 
DHD 
1  ) <  -
THB 
!| DHG 
<«b 
Figure 2: A representative chromatograph of urine samples with H2 type p-glucuronide as the hydrolysis enzyme. Dein: 
daidzein; DHD; dihydro-daidzein; DHG: dihydro-genistein; Gein: genistein; THB: 2,4,4'-trihydroxydeoxybenzoin as the 
internal standard 
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THE COMBBVATION OF DAIDZEIN, GENISTEIN AND THEIR GLUCURONTOES 
ACTIVATED HUMAN NATURAL KILLER CELLS AT NUTRITIONALLY 
RELEVANT CONCENTRATIONS 
A paper to be submitted to Journal of Nutrition 
Van Zhang', Joan E. Cunnick^ and Suzanne Hendrich'"^ 
Abstract 
To characterize modulatory activity and to mimic physiological conditions, a 
combination of the four isoflavones daidzein, genistein and their glucuronide forms in 
amounts at which they are found in human blood plasma after the consumption of soybean 
foods were assayed with human peripheral natural killer (NK) cells and with the NK3.3 cell 
line. The combination of these four compounds, as well as daidzein glucuronide and 
genistein glucuronide alone or these two together, activated NK activity in peripheral blood 
leukocytes (PBLs) at concentrations ranging from 0.25 to 10 |amol/L. Daidzein alone or in 
combination with genistein had a relatively wider activation range than that of genistein, but 
a reduced activation activity was seen above 5 fimol/L. Genistein could activate NK cells at 
concentrations as low as 0.01 [imol/L, but not at 0.001 ^mol/L. Neither daidzein nor 
'Department of Food Science and Human Nutrition. Iowa State University. Ames, I A. 
50010. 
"Department of Microbiology. Iowa State University. Ames, lA. 50010. 
^Corresponding author. Fax:515-294-6193. E-mail: shendric@iastate.edu. 
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genistein activated the NK3.3 cell line at any of the concentrations studied, suggesting that a 
cross-talk existed among PBLs when partially purified human NK cells were used. The 
activation of NK cells is an indirect effect of isoflavones. 
Key words: • Combination • Isoflavone • Natural killer cell • NK3.3 cell line 
Introductioa 
The role of host immune function has become increasingly important in the 
understanding of the mechanisms underlying the body's ability to prevent cancer. Increasing 
evidence has shown that dietary alteration of host immune function is a key component of 
chemoprevention (Watson, 1986; Lowell et al., 1990). Isoflavones are phytochemicals that 
are mainly obtained from soybeans. Epidemiologic data suggest that consumption of 
isoflavone-rich soy foods may contribute to the reduced risk of cancers at many sites 
(Messina et al., 1994). As a weak estrogen and an inhibitor of protein tyrosine kinase, 
isoflavones. especially daidzein (D) and genistein (G) may be able to influence the natural 
immune system which consists of preexisting or rapidly inducible components. Zhang et al. 
(1997) fed various doses of daidzein to Swiss mice for seven consecutive days, observing a 
stimulatory effect on nonspecific inununity, humoral as well as cell-mediated immunity in 
association with high doses of daidzein (20 or 40 mg/kg body weight). Wang et al. (1997) 
demonstrated that daidzein (0.01-10 |amoi/L) potentiated mitogen-stimulated activation of 
murine lymphocytes. 
Natural killer (NK) cells, an important component of the natural immune system, 
provide an early host response to viral, parasitic and bacterial infections. NK cells have been 
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shown to provide resistance to some of these infections and to play important roles in timior 
siirveillance and in the regulation of hemotopoiesis (Scott and Trinchieri, 1995). Tyrosine 
kinase activity is crucial for the activation of NK cells and genistein is a specific inhibitor of 
tyrosine kinases. The effect of genistein and other isoflavones on NK cell activity may 
depend largely on the exposure concentrations. Zhang et al. (1999) found that genistein at 
concentrations < 5 ^mol/L and daidzein and genistein glucuronides (DG and GG) at O.l-IO 
^imol/L significantly enhanced NK cell mediated K562 cancer cell killings. At > 5 jimol/L, 
genistein significantly inhibited NK cytotoxicity. 
After consumption, soybean isoflavones are biotransformed by phase II enzymes into 
conjugates, mainly glucuronides. Based on our human feeding study results and the 
measurements of metabolites in plasma (Zhang et al., 2000), the percentages of isoflavone 
glucuronides could reach 65-75% of total isoflavones in plasma. A quantifiable amount of 
aglycone daidzein and genistein also appeared in plasma. The ratio of DG : GG : D : G at 3 h 
was around 3 : 1 : 0.3 : 0.1. As stated above, a single isoflavone compound and the 
conjugates were able to modulate NK cytotoxicity over a wide range of concentrations. We 
were interested in knowing the effects when these compounds are combined together based 
on our observations from human feeding studies. Although low plasma concentrations were 
found for the aglycone isoflavones in plasma, activation of NK activity was usually seen 
when these concentrations were used in an NK assay. We hypothesized that the combination 
of D and G and their glucuronides would activate NK cells more effectively than the 
glucuronide forms alone at physiological concentration. 
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Materials and methods 
Chemicals 
Recombinant human interieukin 2 (IL-2) was obtained from Sigma (St. Louis, MO.). 
Formaldehyde (16%, Ultra pure) was obtained from Polysciences Inc.(Warrington, PA). 
Sterile sodium chromate (^'Cr) obtained fromNEN Dupont (Boston, MA). Daidzein (D) and 
genistein (G) were chemically synthesized. Daidzein and genistein glucuronides (DG and 
GG) were prepared by the methods described in Zhang et al. (1999). FITC anti-human 
CD16, Biotin anti-human CD56, Biotin Mouse IgGi, k and FITC mouse IgGi, k and 
streptavindin cychrome were all purchased from Pharmingen (San Diego, CA). Gentamicin, 
L-glutamine and HEPES were from Gibco BRL (Grand Island, NY) and fetal bovine serum 
(FBS) from JRH, Biosciences (Lenexa, KS). Lymphocult-T was purchased from Biotest 
Diagnostics Corp (Denville, NJ). 
Cell culture 
A human NK cell line. NK3.3, cloned from a primary mixed lymphocyte culture, was 
kindly provided by Dr. Jacki Kombluth (St. Louis University, St Louis. MO). NK3.3 cell 
line was cultured in RPMI-1640 which contained 2 mmol/L L-glutamine, 25 mM HEPES. 50 
|ig/mL gentamicin, 15% FBS and 15% Lymphocult-T at 3T'C and 7% CO2. Cells were 
maintained at a density of 2.5-3 x 10^ cells/mL. The culture medium and maintenance for 
NK sensitive cancer cell line K562 was the same as described in Zhang et al. (1999). 
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Natural killer activity assay 
Lymphocult-T medium was used to maintain NK3.3 cell line. It contains IL-2 and 
other active components. In order to see the activation by IL-2, NK3.3 cells were activated 
for 18-20 h, then centrifiiged and separated into two parts: one was resuspended in 
Lymphocult-T medium, and another was resuspended in regular NK assay medium. NK 
cytotoxicity was assayed in the presence or absence of IL-2. Lymphocult-T suspensions of 
NK3.3 cells were not assayed with IL-2 due to lack of flirther activation when IL-2 was 
present. 
A total of 14 human subjects, seven females and seven males, participated in the 
current studies. The use of human subjects was approved by the Iowa State University 
Human Subjects Committee. Basically the preparation and assay methods for NK cell 
cytotoxicity were the same as stated in Zhang et al. (1999). The main differences were a 
broader range of isoflavone concentrations. In the NK3.3 cell line study, final G 
concentrations of 0.01, O.l. 0.5, 1 and 5 |imol/L were used. A ratio of Effector : Target of 50 
: 1 was applied. In the first human NK study, in which 6 (3 female and 3 male) human 
subjects participated. G concentration of 0.001 nmol/L was also included. Stock solutions of 
isoflavones were made using 100% DMSO due to their amphipathic /lipophilic nature. 
DMSO content of assay media in both studies was held constant at 0.014% for all isoflavone 
concentrations. In the second human NK cell study, in which 8 (4 female and 4 male) human 
subjects participated. D, G, DG and GG at concentrations of 0.25, 0.5, 5 and 10 nmol/L 
were used. A combined concentration of D+G or DG+GG at concentrations of 0.5, 1 and 10 
jimol/L and a combination of DG, GG, D and G (ratio of 3 : 1 :0.3 :0.1) at concentrations of 
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0.25,0.5, 5 and 10 |imol/L were assayed. DMSO content of assay media in this experiment 
was 0.028%. The Effector: Target ratio in human NK assay was 25 : 1. 
Fluorescent staining of lymphoid cells 
Separate aliquots (100 }iL) of lymphocyte suspensions were diluted with 0.1% PBS 
azide (cold) and stained with either 10 jiL FITC anti-human CD16 (clone 3G8) and 10 
Biotin anti-human CD56 (clone B159), or an equivalent amount of isotype control (mouse 
IgGi-biotin and mouse IgGi-FlTC). The solutions were incubated at 4°C in the dark for 30 
min and washed with PBS 0.1% azide. The contaminated red blood cells were lysed with 
ammonium chloride buffer (pH = 7.4). A second step of 0.04 ng strept-Avidin Cychrome 
was applied. Cells were fixed with 2% PBS paraformaldehyde prior to EPICS-XL-MCI 
(Coulter, Miami, FL) flow cytometry analysis. Gates were set to distinguish CD 16 and 
CD56 cells. 
Statistical analysis 
Log-transformation was applied to all the NK cytotoxicity data to achieve 
homogeneity of variance before ANOVA. SAS version 6.06 (SAS Institute, Cary, NC) was 
used for statistical analysis. A two-way ANOVA was used to compare isoflavones over 
three concentrations with and without IL-2. Individual treatment differences were 
determined using student t-test. The percentages of cells carrying CD56'*^ alone or CD56'^16^ 
were compared between sexes using two-way ANOVA and combined with covariance for 
the percentage of NK cytotoxicity. Differences were considered to be significant at /? < 0.05. 
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Results 
For purposes of standardization, and due to the variation of NK activity among assays 
and across subjects, NK cytotoxicity in the absence of IL-2 and isoflavones was set at 100% 
(ranging from 8.5 to 46.2% in the first six persons, and from 16.6 to 37.7% in the rest 8 
persons). All the NK cytotoxicity data were transformed to percentage baseline. 
NK3.3 cell line. Removing lymphocult-T medium from NK3.3 cells after 18-20 h 
activation and resuspending them in regular NK assay medium prior to cytotoxic assay was 
an attempt to mimic conditions used for peripheral blood NK cells. In the absence of IL-2, 
about 8% activation over baseline was seen at the concentrations of 0.5 or 1.0 ^imol/L for D 
or G respectively. In the presence of IL-2, the cytotoxicity of NK3.3 cells was below 
baseline with the addition of D. Treatment of lymphocult-T resuspended NK3.3 cells with D 
or G only raised the killing ability marginally to about 5% over control. However, no 
significant differences were found for all the isoflavone treatments. The results presented in 
Fig. 1 were the average of 4 repeated measurements. 
Peripheral NK cells. Six human subjects were recruited to study the influence of low 
dose genistein on NK cytotoxicity in vitro. In addition to those doses (0.1-5 jimol/L) 
presented in Zhang et al. (1999), two new lower doses (0.001 and 0.01 |imol/L) were 
included (Fig.2). The overall estimation showed that all the concentrations of isoflavones 
were significantly (p < 0.01) different from 0 |imol/L control, except for genistein at 0.001 
and O.Ol jimol/L. Significant differences {p = 0.0001) were found between the treatment of 
PBL with and without IL-2. There were significant differences {p = 0.0001) in the 
cytotoxicity among different concentrations of genistein, with 5 |imol/L of genistein 
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significantly inhibiting the NK cytotoxicity and other genistein concentrations activating NK 
cells. 
Four concentrations (0.25, 0.5, 5 and 10 (imol/L) were included to study the effects of 
the combined compounds (DG, GG, D and G at ratio of 3 ; 1 : 0.3 : 0.1) on NK activity 
(Fig3A&B). As a comparison, each single compound was also included and assayed at the 
same concentrations. Again, significantly (p = 0.0001) increased NK cytotoxicity was seen 
with the addition of IL-2. However, there was no interaction of 11-2 with isoflavone 
concentrations. G activated NK cell killing within a very narrow range. Above 0.5 ^mol/L. 
a decrease in lytic activity was seen. At G concentrations of 5 and 10 |imol/L, a significant 
(p < 0.001) inhibition of NK killing activity was seen. D had a relatively wider activation 
range than that of G. At 10 |imol/L, we saw decreased lytic activity ofNK cells, but it was 
not significantly {p = 0.44) different from control. 
The activation of NK cell activity by DG, GG and 4 compounds combined across all 
the concentrations were all significantly (/? < 0.01) greater than that of control. Interestingly, 
the combination of 4 compoimds activated the NK cells less than DG, GG, the single 
compound D when compared at the same concentrations, but this difference was not 
statistically significant. In the presence of IL-2, D, G, DG, GG and 4 compounds combined 
additively increased NK cytotoxicity at the concentrations used (Fig. 3A). 
The combination of D with G, and DG with GG were compared at concentrations of 
0.5,1 andlO jomol/L as well (Fig. 4). Daidzein was less toxic at high concentrations (10 
Hmol/L) to NK cells than was G. Even though D+G together (log Ismean = 3.44) still 
significantly inhibited NK cytotoxicity, the actual NK cytotoxicity was greater than 10 
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|imol/L G (log Ismean = 3.25) used alone. At lower concentrations, D+G was as active as 
each compound alone. The combination of DG+GG activated NK cells at all the 
concentrations, and they were all significantly greater than control. 
A significant gender difference was seen in the NK cytotxicity response to IL-2 (Fig. 
5) and was indicated by a significant interaction of gender and IL-2 (p < 0.001). Males had 
greater response to IL-2 than did females. However, no gender differences were found in the 
response to isoflavones. 
Fluorescent staining. The average total population of CD56'' cells among 14 
subjects was 23.0±9.1%, and the average €056"^16"^ was 18.0±6.7%. The population of 
CD56'CD16* was not great in people (ranging from 1.2-11.5%), but the NFG.3 cell line 
(rested) has a relatively high percentage ofCD56"CDl6"^ (25.3%). After activation for 18-20 
h, the CD56*CD16* in NK3.3 cell line was increased to 28.6%. A very low percentage of 
CD56^CD16^ was found inNK3.3 cell line, with 1.8% in rested cells and 4.0% in activated 
cells. 
We used the percent total CD56^ and €056*16"^ as covariates to examine gender 
differences in response to isoflavones and IL-2. However, there was no effect of gender on 
baseline cytotoxicity. When IL-2 effects were considered, there was significant difference {p 
< 0.05) between genders in their response to IL-2. 
Discussion 
NK cells have been recognized as earliest effector cells responsible for the 
elimination of blood-bome metastases. NK activity appears to be important in the 
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progression of cancer since people who have low NK activity at diagnosis tend to develop 
metastases more frequently than those with normal levels of NK activity (Whiteside and 
Herberman, 1994). Patients with congenital or acquired immunodeficiencies, including the 
absence or defective function of NK cells, developed at a relative high frequency of certain 
types of malignancies, particularly lymphomas, leukemias and Kaposi's sarcomas (Ho et al., 
1988; Rosen et al., 1995; UUum et al., 1995). Not only in patients with hematological 
malignancies, but also in those with solid tissue cancers, levels of NK activity have been 
documented to decrease in concert with disease progression. Patients with advanced 
metastases often have abnormalities in NK cell function and /or NK cell numbers (Zeigler et 
al., 1981; Introna and Montavani, 1983). In non-cancer bearing people, increasing age is 
associated with decreased NK activity (Meydani et al., 1988). Increasing NK activity in both 
non-cancer bearing and in tumor-bearing individuals may help prevent or slow the 
progression of tumor metastases. 
As a potential cancer preventive agent, soybean isoflavones genistein and the 
glucuronide forms of daidzein and genistein showed NK activation activity at low 
concentrations of 0.1-5 and 0.1-10 ^mol/L respectively in a previous study (Zhang et aL, 
1999). In the present study, we further investigated NK modulation by soybean isoflavones 
examining the combination of the main plasma isoflavone metabolites. At total 
concentrations of 0.25-10 ^imol/L, the combination of D, G. DG and GG activated NK cell 
cytotoxicity as significantly as DG, GG used alone or together, which demonstrate that 
isoflavones and their metabolites can be combined to be an effective NK activator in vitro. 
Although we had hypothesized that the natural combination of isoflavones would be more 
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potent as an NK activator, it is not surprising that the activating effect was similar to the 
individual isoflavone as they may all act through a similar mechanism. 
Many investigators have suggested plausible explanations that may account for the 
observed cancer chemoprevention of soy isoflavones. However, the doses required to show 
those mechanisms in vitro are usually pharmacological f> 50 (omol/L). The maximum 
plasma level in soy consumption was reported to reach 7-8 |imol/L or lower after hydrolysis 
of metabolites to parent isoflavone aglycones (Barnes et al., 1995; Xu et al., 1995; Zhang et 
al., 2000). Based on our recent human feeding study results (Zhang et al., 2000), about 15% 
of total isoflavones were present in plasma as aglycones and 60% of isoflavones as 
glucuronides. The circulating levels of aglycone isoflavones after typical soy consumption 
may be unlikely to exceed 1 (imol/L. Based on these results, we generated a ratio for these 
major isoflavone metabolites (DG : GG : D : G at 3: I : 0.3 : 0.1) and used it in our NK 
cytotoxicity study. The highest concentration for the combined compounds was set at 10 
(imol/L, a concentration which could be observed from feeding study. Therefore, the 
concentrations we used in this study were well within physiologically relevant concentrations 
for human consumption. 
As a comparison, each single compound was assayed at the same concentrations as 
the four compounds in combination. DG and GG were active over a broader range than 
previously seen with G as before (Zhang et al., 1999). D had similar NK activation activity 
as G at lower concentrations (below 5 i^mol/L). The activation range of D may be broader 
than G since at 10 |imol/L, the effect of D was not significantly different from baseline, but 
G significantly suppressed NK activity at this concentration. When D and G were combined. 
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the log Ismeans for D+G at concentration of 10 jimol/L was 3.44. It was in between D and G 
(log lemeans 3.61 and 3.26, respectively) when they were used alone, which indicated that 
both isoflavones probably function at the same site to modulate NK activity. 
This study also extended observations from our previous study (Zhar^ et al.. 1999). 
Two lower concentrations (0.01 and 0.001 ^mol/L) of G were assayed (Fig 2). NK cell 
cytotoxicity was marginally increased with the addition of 0.001 |imol/L G but it did not 
differ from the control. The significantly increased activation of NK cells with addition of 
isoflavones was extended from O.l |imol/L in the previous study to concentration as low as 
0.01 |imol/L in the current study. 
NK cells from male subjects had significantly greater response to exogenous IL-2 
than female's NK cells (Fig. 5). Gender differences have been shown in lymphokine 
production (Tollerud et al., 1989) and in immune response to exogenous compounds like 
cocaine (Xu et al., 1997). Brett et al. (1999) reported that male peripheral blood lymphocytes 
showed a significant increase in NK cell cytotoxicity when preincubated with 5 U/mL lL-2 
for 70 h, while female cells failed to do so at this concentration. In our study, both males and 
females had a robust responses to IL-2 and males had a greater response to IL-2 (0.5 ng/well) 
with a 4.5 h incubation. However, no interaction was found with isoflavone and IL-2 
treatments, and all the subjects responded to isoflavone treatments in a similar way. In our 
previous study (Zhang et al., 1999), we postulated that isoflavone activated NK cells from a 
site different from IL-2. Our current study further confirmed this view. Isoflavones have 
similar structures as the natural estrogen, estradiol and had weak estrogenic activity in some 
biological systems (Farmakalidis and Murphy, 1984; Song et al., 1999). In female rats, a 
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diminished natural killer cell activity was observed with short term exposure to elevated 
estradiol and low progesterone levels (Ben-Eliyahy et al., 1996). If estrogenic activity is the 
mechanism that could explain isoflavone effects, we would have expected a different 
response in males and females to isoflavones. Apparently, other mechanisms rather than 
estrogenecity should be considered in isoflavone's NK activation functions. 
Research on NK cell biology using partially purified NK cells cannot distinguish 
cytotoxicity due to other immune cells, or rule out possible cross-talk between other cell 
types as an activation mechanism, or solve the problem of collecting an adequate quantity of 
pure NK cells from peripheral blood. The NK3.3 cell line was used. It was produced by 
harvesting peripheral blood leukocytes by density gradient centriiligation from heparinized 
blood from two healthy blood providers by Dr. Jacki Kombluth (St. Louis University). This 
cell line has been used to provide explanations for biochemical and molecular events related 
to NK cell fimctions (Cone et al., 1993; Ortaldo et al., 1997; Umehara et al., 1997; Zhou et 
al.. 1997). We used this cell line to help clarify the effects of isoflavones on NK cell activity, 
Several aspects were noticed with this cell line. The sensitivity of the K562 cancer ceils to 
NK3.3 cell killing was not as strong as they are to the peripheral NK cells, so a higher 
Effector: Target ratio (50 :1 instead of 25 : I) was used for the cell line. This cell line was 
mainly of the CD56"CD16^ population, but NK cells separated from human peripheral blood 
were mainly CD56^ cells. NK3.3 cells are IL-2 dependent. After depletion of the medium 
and switching to regular NK assay medium, the NK cell line had a relatively lower response 
to IL-2 compared to the strong response by most human NK cells. The average percentage 
of killing after adding IL-2 over non-IL-2 treatment was 176% (ranging from 116-219%) in 
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NK3.3 cell line and 196% (ranging from 152-247% from 8 subjects) in humaiL The different 
response of NK3.3 cell line to IL-2 in each experiment was similar to the variability observed 
in humans. No additional activation was seen with IL-2 in the lymphocult-T medium, but the 
cytotoxicity by lymphocult-T medium alone (241%) was much greater than after the addition 
of TL-2 to the NK assay medium indicating that other components in the lymphocult-T 
medium were also important in activating the NBG.3 cell line. 
No effect was seen with the addition of D or G at ail the concentrations in NK3.3 
cells (Fig. 1). A significant increase in cytotoxicity was seen with human peripheral blood 
NK cells when D or G was added at concentrations of 0.01-1 ^mol/L (Fig. 2), which 
increased to a wider range of concentrations (up to 10 |imoI/L) when DG or GG was added 
(Fig. 3). Our initial goal was to use the cell line to probe the molecular mechanism of the 
activation with isoflavones seen in human peripheral blood lymphocytes. We did not achieve 
this purpose. Clearly, a cross-talk existed within cells when we used partially purified 
peripheral NK cells. NK cells are regulated by numerous factors. Secretion of specific 
cytokines or regulation by specific cytokines from other cells are important effectors of NK 
cells. The most potent activators of NK cells are IL-2 (which we added), IL-12. IFN-y 
(Sivakumar et al., 1998). To a lesser degree the following cytokines are also known to 
activate NK cells: IL-1, IL-15 and IFN-a and P (Kuby, 1997). It will be interesting to know 
which cytokine secretions are changed after co-culturing peripheral NK cells with 
isoflavone(s) within the assay period. 
In simimary, the present study provided direct in vitro evidence that isoflavones in 
combination of daidzein, genistein and their glucuronides activated NK cells within 
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nutritionally relevant concentrations. Studies with NK3.3 cell line indicated that the 
activation observed with isoflavones came from an indirect effect of isoflavones on NK cells. 
Further studies are needed in order to clarify the mechanisms involved in NK modulation 
activity by isoflavones and to provide more support for their cancer preventive effects. 
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Figure 1: Cytotoxicity ofNK3.3 cell line against K562 target cells, expressed as percentage 
of baseline cytotoxicity. Each point represents the average of four different experiments 
from triplicate assays. In between the concentrations of 0.1 -1 jimol/L, both compounds D 
and G marginally increased NK3.3 activity except D at the presence of IL-2. However, both 
compounds did not statistically significantly change NK3.3 cell's killing ability. Significant 
differences (p = 0.001) were seen among the three media treatments: NK assay media with or 
without IL-2, and the lymphocuIt-T media. D = daidzein; G = genistein; lymp represent 
lymphocuIt-T media. The regular NK assay media treatment with or without IL-2 was not 
specifically labeled in the graph, but are represented by the 0 ^mol/L isoflavone 
concentrations. 
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Figure 2: Cytotoxicity of human peripheral blood natural killer cells against K562 target 
cells, expressed as percentage of baseline cytotoxicity. Genistein incubated with or without 
interleukin 2 (IL-2) (0.5 ng/well) was shown in this graph. Each point represents the mean 
cytotoxicity in 6 subjects from triplicate assays. Genistein at concentrations of 0.01 nmol/L 
and below marginally but not statistically significantly increased NK killing. Symbol * 
denotes the significant increase in NK cytotoxicity at concentrations of 0.1 -1 jimoi/L 
compared to control (p = 0.001). Symbol + represents the significant (p = 0.0001) decrease 
of NK activity at 5 [xmol/L of genistein compared to control. G = genistein. 
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Figure 3: Cytotoxicity of human peripheral blood natural killer cells against K562 target 
cells, expressed as percentage of baseline killing. Each point in both graphs represents the 
mean cytotoxicity in 8 subjects. Graph A represents the individual results of 4 different 
isoflavone compounds (D, G, DG and GG) and the combination of these 4 compounds at 
concentrations of 0.25-10 umol/L incubated with and without IL-2 (0.5 ng/well). Graph B is 
the overall analysis collapsing across IL-2 treatment. The four compounds in combination at 
all concentration were significantly different from baseline. Genistein at concentrations of 5 
and 10 |j.mol/L were significantly different from baseline {p = 0.001). Symbol • represents 
the significant increase in NK cytotoxicity of the compound cluster. Symbol # indicates that 
no differences were found compared to baseline. Symbol + represents the significant 
decrease with the adding of isoflavone in NK cell killing ability. D = daidzein; G = 
genistein; DG = daidzein glucuronide; GG = genistein glucuronide; 4C = combination of D, 
G. DG and GG. 
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Figiire 4: Results of two isoflavone combinations: D+G and DG+GG at three different 
concentrations (0.5,1 and 10 |imol/L) incubated with and without IL-2 (0.5 ng/well). The 
overall estimation indicated that both combinations cross all the concentrations were 
significantly (p < 0.01) different from control. Symbols have the same meaning as in Figure 
3. 
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Figure 5: Comparison of cytotoxicity differences in gender in response to IL-2. Each point 
represents the average from 4 persons. Males had significantly greater response to II--2 than 
did females. Interaction of IL-2 * gender was significant at p = 0.0001. 
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GENERAL CONCLUSIONS 
Glycitein, as the third main isoflavone that is found in soy foods, has not attracted 
enough attention. There are few reports about glycitein's biological activity as well as its 
bioavailability. Our human feeding study showed that glycitein had similar bioavailability to 
daidzein, and was more bioavailable than genisteiru A gender difference was seen with 
isoflavone bioavailability which needs to be fiirther explored. 
Most studies about isoflavones are focused on their aglycone forms. Not too much 
research has been done with the major glucuronide metabolites. By using selective 
hydrolytic enzymes, our human feeding study showed that daidzien and genistein 
glucuronides were the dominant forms in plasma and in urine. A detectable amount of the 
aglycones daidzein and genistein also appeared in plasma. As the major metabolic forms 
appearing in circulation, the glucuronides might contribute to biological effects observed 
with isoflavones. 
As an early line of defense, natural killer (NK) cells play an important role against 
cancer and some infections. It is important to keep NK cells active or to increase their 
activity. Daidzein and genistein glucuronides, the main metabolites in the circulation were 
assayed for their NK activation activity when they were in combination with the aglycone 
daidzein and genistein in nuUitionally relevant ratios and concentrations. Our results showed 
that the combination of these four compounds activated human NK cells to the same level as 
each glucuronide used alone, and activated across a wider concentration range than the 
aglycones alone. No effect of isoflavone treatment was seen on the NK3.3 cell Ime, 
indicating that isoflavones activated NK activity indirectly. Our results suggested that 
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glucnronide forms had some biological activity, at least in in vitro. Isoflavone glucuronide 
activities in other biological systems should not be ignored. 
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